☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
36-4813934
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
Title of each class
|
|
Trading
S
ym
bol
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value per share
|
|
CMPI
|
|
The Nasdaq Global Market
|
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated
filer
|
☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
|
•
|
|
We are a clinical-stage biopharmaceutical company with a very limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur substantial and increasing net losses in the foreseeable future. We may never achieve or sustain profitability.
|
|
•
|
|
A pandemic, epidemic, or outbreak of an infectious disease, such as the global novel coronavirus disease 2019
(“COVID-19”)
pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third-parties on whom we rely, our supply chain, our ability to raise capital, and our financial results.
|
|
•
|
|
We have never generated any revenue from product sales, and our ability to generate revenue from product sales and become profitable will depend significantly on our success in achieving a number of goals and on other factors.
|
|
•
|
|
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our research, product development or commercialization efforts.
|
|
•
|
|
We are heavily dependent on the success of vidutolimod (formerly
CMP-001),
our only current product candidate.
|
|
•
|
|
We will not be able to commercialize vidutolimod and future product candidates if our preclinical studies do not produce successful results and our clinical trials do not demonstrate the safety and efficacy of vidutolimod and future product candidates.
|
|
•
|
|
Vidutolimod is based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.
|
|
•
|
|
Difficulty in enrolling patients could delay or prevent clinical trials of vidutolimod and future product candidates. We may find it difficult to enroll patients in our clinical trials or any subsequent trials that we may conduct.
|
|
•
|
|
Vidutolimod is being, and future product candidates may be, evaluated in combination with third-party drugs, and we do not have control over the supply, regulatory status, or regulatory approval of such drugs.
|
|
•
|
|
We currently rely on third-party contract manufacturing organizations (“CMOs”) for the production of clinical supply of vidutolimod and may rely on CMOs for the production of commercial supply of vidutolimod, if approved. This reliance on CMOs increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.
|
|
•
|
|
We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform satisfactorily, we may be unable to obtain regulatory approval for vidutolimod or any future product candidates or any approvals that may be obtained may be delayed.
|
|
•
|
|
Our collaboration agreements with any future third-parties may not be successful, which could adversely affect our ability to develop and commercialize vidutolimod or any future product candidates.
|
|
•
|
|
The regulatory approval processes of the U.S. Food and Drug Administration (the “FDA”) and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize vidutolimod and future product candidates as expected, and our ability to generate revenue may be materially impaired or eliminated.
|
|
•
|
|
Our relationships with patients and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.
|
|
•
|
|
We face significant competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If competitive product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated.
|
|
•
|
|
If we are unable to obtain, maintain and protect our intellectual property rights for our technology and our product candidates, or if our intellectual property rights are inadequate, our competitive position could be harmed.
|
|
•
|
|
Our success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
|
|
•
|
|
our current expectations and anticipated results of operations;
|
|
•
|
|
the timing and the success of preclinical studies and clinical trials of vidutolimod and future product candidates, including our current Phase 2 trial for
anti-PD-1
|
|
•
|
|
the initiation and completion of any clinical trials of vidutolimod and future product candidates;
|
|
•
|
|
the ongoing impact of the
COVID-19
pandemic on our business;
|
|
•
|
|
our need to raise additional funding before we can expect to generate any revenues from product sales and our ability to raise capital, including in light of the impact of the
COVID-19
global pandemic and the related potential impact on the US and global economies;
|
|
•
|
|
our ability to conduct successful clinical trials or obtain regulatory approval for vidutolimod or any future product candidates that we may identify or develop;
|
|
•
|
|
our ability to ensure adequate supply of vidutolimod and any future candidates;
|
|
•
|
|
our ability to maintain third-party relationships necessary to conduct our business;
|
|
•
|
|
our dependence upon the success of our research to generate and advance additional product candidates;
|
|
•
|
|
our ability to establish an adequate safety and efficacy profile for vidutolimod or any future product candidates that we may pursue;
|
|
•
|
|
the implementation of our strategic plans for our business, vidutolimod and any other product candidates we may develop and our technology;
|
|
•
|
|
our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
|
|
•
|
|
the rate and degree of market acceptance and clinical utility for vidutolimod and any other product candidates we may develop;
|
|
•
|
|
our estimates about the size of our market opportunity;
|
|
•
|
|
our ability to maintain and establish collaborations and strategic relationships, including our clinical trial collaborations with an affiliate of Merck KGaA (“Merck”), Pfizer Inc. (“Pfizer”), Bristol-Myers Squibb Company (“BMS”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”);
|
|
•
|
|
the potential benefits of the continued research, development, testing and manufacturing services provided by contract manufacturing organizations;
|
|
•
|
|
our financial performance and liquidity;
|
|
•
|
|
our ability to effectively manage our anticipated growth;
|
|
•
|
|
developments relating to our competitors and our industry, including the impact of government regulation;
|
|
•
|
|
our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;
|
|
•
|
|
our ability to maintain adequate internal controls over financial reporting;
|
|
•
|
|
our expectations regarding the period during which we qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act (the “JOBS Act”);
|
|
•
|
|
our expectations regarding the period during which we qualify as a “smaller reporting company”;
|
|
•
|
|
our use of proceeds from our initial public offering and our expectations regarding our estimated expenses, the sufficiency of our cash resources, our expected cash runway and our need for additional financing, and
|
|
•
|
|
other risks and uncertainties, including those listed under the section titled “Risk Factors.”
|
June 30,
2021 |
December 31,
2020 |
|||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$ | 63,110 | $ | 43,055 | ||||
Restricted cash
|
20 | 20 | ||||||
Short-term investments
|
22,240 | 51,831 | ||||||
Prepaid expenses and other current assets
|
5,704 | 7,195 | ||||||
|
|
|
|
|||||
Total current assets
|
91,074 | 102,101 | ||||||
|
|
|
|
|||||
Investments,
non-current
|
10,240 | 30,973 | ||||||
Machinery and equipment, net
|
367 | — | ||||||
|
|
|
|
|||||
Total assets
|
$ | 101,681 | $ | 133,074 | ||||
|
|
|
|
|||||
Liabilities and Stockholders’ Equity
|
||||||||
Current Liabilities:
|
||||||||
Accounts payable
|
$ | 2,198 | $ | 2,297 | ||||
Accrued expenses
|
4,504 | 5,578 | ||||||
|
|
|
|
|||||
Total current liabilities
|
6,702 | 7,875 | ||||||
|
|
|
|
|||||
Total liabilities
|
6,702 | 7,875 | ||||||
|
|
|
|
|||||
Commitments and Contingencies (Note 9)
|
||||||||
Stockholders’ Equity:
|
||||||||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares outstanding as of June 30, 2021 and December 31, 2020
|
— | — | ||||||
Common stock, $0.0001 par value; 300,000,000 authorized as of June 30, 2021 and December 31, 2020; 21,625,891 and 21,560,398 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively
|
2 | 2 | ||||||
Additional
paid-in
capital
|
268,179 | 265,342 | ||||||
Accumulated other comprehensive gain (loss)
|
(33 | ) | (74 | ) | ||||
Accumulated deficit
|
(173,169 | ) | (140,071 | ) | ||||
|
|
|
|
|||||
Total stockholders’ equity
|
94,979 | 125,199 | ||||||
|
|
|
|
|||||
Total liabilities and stockholders’ equity
|
$ | 101,681 |
$
|
133,074 | ||||
|
|
|
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
$ | 14,865 | $ | 6,476 | $ | 25,243 | $ | 12,789 | ||||||||
General and administrative
|
4,090 | 1,795 | 7,893 | 3,305 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses
|
18,955 | 8,271 | 33,136 | 16,094 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations
|
(18,955 | ) | (8,271 | ) | (33,136 | ) | (16,094 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Other income (expense), net:
|
||||||||||||||||
Interest income
|
20 | 6 | 73 | 28 | ||||||||||||
Loss on sale of
available-for-sale
|
(35 | ) | — | (35 | ) | — | ||||||||||
Change in fair value of convertible loan notes
|
— | (83 | ) | — | (83 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total other income (expense), net
|
(15 | ) | (77 | ) | 38 | (55 | ) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss
|
$ | (18,970 | ) | $ | (8,348 | ) | $ | (33,098 | ) | $ | (16,149 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Reconciliation of net loss attributable to common stockholders:
|
||||||||||||||||
Net loss
|
$ | (18,970 | ) | $ | (8,348 | ) | $ | (33,098 | ) | $ | (16,149 | ) | ||||
Accretion of issuance costs on redeemable convertible preferred stock
|
— | (429 | ) | — | (456 | ) | ||||||||||
Accrued dividends on redeemable convertible preferred stock
|
— | (2,187 | ) | — | (3,957 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss attributable to common stockholders
|
$ | (18,970 | ) | $ | (10,964 | ) | $ | (33,098 | ) | $ | (20,562 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Weighted-average common shares outstanding—basic and diluted
|
21,624,568 | 1,488,489 | 21,603,563 | 1,488,489 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss per share attributable to common stockholders—basic and diluted
|
$ | ( 0.88 | ) | $ | (7.37 | ) | $ | (1.53 | ) | $ | (13.81 | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
los
s
|
|
$
|
(18,970
|
)
|
|
$
|
(8,348
|
)
|
|
$
|
(33,098
|
)
|
|
$
|
(16,149
|
)
|
Unrealized gain on available-for-sale investments
|
|
|
50
|
|
|
|
—
|
|
|
|
41
|
|
|
|
—
|
|
Comprehensive loss
|
|
$
|
(18,920
|
)
|
|
$
|
(8,348
|
)
|
|
$
|
(33,057
|
)
|
|
$
|
(16,149
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A Redeemable
Convertible Preferred Stock |
|
|
Series B Redeemable
Convertible Preferred Stock |
|
|
Series C Redeemable
Convertible Preferred Stock |
|
|
Common Stock
|
|
|
Additional
Paid-In
Capital
|
|
|
Accumulated
Deficit
|
|
|
Accumulated
Other Comprehensive Gain/(Loss) |
|
|
Total
Stockholders’ Equity (Deficit) |
|
||||||||||||||||||||||||
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
||||||||||||||||||||||||
Balances at December 31, 2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
|
$
|
—
|
|
|
|
21,560,398
|
|
|
$
|
2
|
|
|
$
|
265,342
|
|
|
$
|
(140,071
|
)
|
|
$
|
(74
|
)
|
|
$
|
125,199
|
|
Exercise of stock options
|
— | — | — | — | — | — | 59,225 | — | 118 | — | — | 118 | ||||||||||||||||||||||||||||||||||||
Stock-based
compensation expense
|
— | — | — | — | — | — | — | — | 1,216 | — | 1,216 | |||||||||||||||||||||||||||||||||||||
Unrealized
losses on available-for-sale investments |
— | — | — | — | — | — | — | — | — | — | (9 | ) | (9 | ) | ||||||||||||||||||||||||||||||||||
Net loss
|
— | — | — | — | — | — | — | — | — | (14,128 | ) | — | (14,128 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Balances at March
31, 2021 |
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
21,619,623
|
|
|
2
|
|
|
266,676
|
|
|
(154,199
|
)
|
|
(83
|
)
|
|
112,396
|
|
||||||||||||
Exercise of
stock options |
— | — | — | — | — | — | 6,268 | — | 16 | — | — | 16 | ||||||||||||||||||||||||||||||||||||
Stock-based compensation expense
|
— | — | — | — | — | — | — | — | 1,487 | — | — | 1,487 | ||||||||||||||||||||||||||||||||||||
Unrealized
gains on available-for- sale investments |
— | — | — | — | — | — | — | — | — | — | 50 | 50 | ||||||||||||||||||||||||||||||||||||
Net loss
|
— | — | — | — | — | — | — | — | — | (18,970 | ) | — | (18,970 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Balances at June
30, 2021 |
—
|
|
$
|
—
|
|
—
|
|
$
|
—
|
|
—
|
|
$
|
—
|
|
|
21,625,891
|
|
$
|
2
|
|
$
|
268,179
|
|
$
|
(173,169
|
)
|
$
|
(33
|
)
|
$
|
94,979
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A Redeemable
Convertible Preferred Stock |
|
|
Series B Redeemable
Convertible Preferred Stock |
|
|
Series C Redeemable
Convertible Preferred Stock |
|
|
Common Stock
|
|
|
Additional
Paid -
In
|
|
|
Accumulated
|
|
|
Accumulated
Other Comprehensive |
|
|
Total
Stockholders’ |
|
||||||||||||||||||||||||
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Gain/(Loss)
|
|
|
Equity (Deficit)
|
|
||||||||||||
Balances
31, 2019 |
|
25,000,000
|
|
$
|
32,482
|
|
|
26,283,386
|
|
$
|
64,446
|
|
|
—
|
|
$
|
—
|
|
|
1,488,489
|
|
$
|
1
|
|
$
|
—
|
|
$
|
(97,437
|
)
|
$
|
—
|
|
$
|
(97,436
|
)
|
||||||||||||
Issuance of series B redeemable convertible preferred
$2.1687
per
$27
net of issuance costs of |
— | — | 3,688,898 | 7,973 | — | — |
—
|
— | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Exercise of series B preferred stock tranche right
|
— | — | — | 300 | — | — |
—
|
— | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Accretion of
issuance costs related to redeemable convertible preferred stock |
— | — | — | 27 | — | — |
—
|
— | — | ( 27 | ) | — | ( 27 | ) | ||||||||||||||||||||||||||||||||||
Stock-based compensation expense
|
— | — | — | — | — | — |
—
|
— | 101 | — | — | 101 | ||||||||||||||||||||||||||||||||||||
Accrued dividends on redeemable convertible preferred stock
|
— | 498 | — | 1,272 | — | — |
—
|
— | (101 | ) | (1,669 | ) | — | (1,770 | ) | |||||||||||||||||||||||||||||||||
Net loss
|
— | — | — | — | — | — |
—
|
— | — | (7,801 | ) | — | (7,801 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Balances at March 31, 2020
|
|
25,000,000
|
|
|
32,980
|
|
|
29,972,284
|
|
|
74,018
|
|
|
—
|
|
|
—
|
|
|
1,488,489
|
|
|
1
|
|
|
—
|
|
|
(106,934
|
)
|
— |
|
(106,933
|
)
|
||||||||||||||
I
ssuance of series C redeemable convertible preferred stock at
$1.6016
per
$429
net of issuance costs of |
— | — | — | — | 46,828,167 | 74,571 | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Conversion of convertible notes into series C convertible redeemable preferred stock
|
— | — | — | — | 6,295,756 | 10,083 | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Accretion of
issuance costs related to redeemable convertible preferred stock |
— | — | — | — | — | 429 | — |
—
|
— | (429 | ) | — | (429 | ) | ||||||||||||||||||||||||||||||||||
Stock-based
compensation expense
|
— | — | — | — | — | — | — | — | 100 | — | — | 100 | ||||||||||||||||||||||||||||||||||||
Accrued dividends
on redeemable convertible preferred stock |
— | 499 | — | 1,296 | — | 392 | — | — | (100 | ) | (2,087 | ) | — | (2,187 | ) | |||||||||||||||||||||||||||||||||
Net loss
|
— | — | — | — | — | — | — | — | — | (8,348 | ) | — | (8,348 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Balances at June 30, 2020
|
|
25,000,000
|
|
$
|
33,479
|
|
|
29,972,284
|
|
$
|
75,314
|
|
|
53,123,923
|
|
$
|
85,475
|
|
|
1,488,489
|
|
$
|
1
|
|
$
|
—
|
|
$
|
(117,798
|
)
|
$
|
—
|
|
$
|
(117,797
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
||||||||
2021
|
2020
|
|||||||
Cash flows from operating activities
|
||||||||
Net loss
|
$ | (33,098 | ) | $ | (16,149 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Stock based compensation
|
2,703 | 201 | ||||||
Depreciation
|
11 | — | ||||||
Change in fair value of notes payable
|
— | 83 | ||||||
Amortization/accretion of investments
|
370 | — | ||||||
Change in operating assets and liabilities:
|
||||||||
Prepaid expenses and other current assets
|
1,491 | (610 | ) | |||||
Accounts payable
|
(98 | ) | (31 | ) | ||||
Accrued expenses
|
(1,075 | ) | 464 | |||||
|
|
|
|
|||||
Net cash used in operating activities
|
(29,696 | ) | (16,042 | ) | ||||
|
|
|
|
|||||
Cash flows from investing activities
|
||||||||
Purchases of investments
|
(10,197 | ) | — | |||||
Maturities of investments
|
29,500 | — | ||||||
Sale of investments
|
30,692 | — | ||||||
Purchase of machinery and equipment
|
(378 | ) | — | |||||
|
|
|
|
|||||
Net cash provided by investing activities
|
49,617 | — | ||||||
Cash flows from financing activities
|
||||||||
Proceeds from stock option exercises
|
134 | — | ||||||
Cash paid for initial public offering costs
|
— | (398 | ) | |||||
Proceeds from issuance of convertible preferred stock, net of issuance costs
|
— | 82,544 | ||||||
Proceeds from issuance of convertible loan notes
|
— | 10,000 | ||||||
|
|
|
|
|||||
Net cash provided by financing activities
|
134 | 92,146 | ||||||
|
|
|
|
|||||
Net increase in cash, cash equivalents and restricted cash
|
20,055 | 76,104 | ||||||
Cash, cash equivalents and restricted cash at beginning of period
|
43,075 | 4,205 | ||||||
|
|
|
|
|||||
Cash, cash equivalents and restricted cash at end of period
|
$ | 63,130 | $ | 80,309 | ||||
|
|
|
|
|||||
Supplemental disclosure of
non-cash
financing activities:
|
||||||||
Accretion of issuance costs to redeemable convertible preferred stock
|
$ | — | $ | 456 | ||||
Exercise of Series B preferred stock tranche right
|
$ | — | $ | 300 | ||||
Accrued dividends on redeemable convertible preferred stock
|
$ | — | $ | 3,957 | ||||
Conversion of loan notes into series C preferred stock
|
$ | — | $ | 10,083 | ||||
Deferred offering costs included in prepaid expenses and other current assets and accounts payable or accrued
|
$ | — | $ | 1,217 |
|
|
Amortized
Cost
|
|
|
Unrealized
Gains
|
|
|
Unrealized
Losses
|
|
|
Fair
Value
|
|
|
Short-term
Investments |
|
|
Investments,
non-current
|
|
||||||
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
||||||
Commercial paper
|
$ | 2,991 | $ | — | $ | — | $ | 2,991 | $ | 2,991 | $ | — | ||||||||||||
Corporate debt securities
|
29,522 | — | (33 | ) | 29,489 | 19,249 | 10,240 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total
|
$ | 32,513 | $ | — | $ | (33 | ) | $ | 32,480 | $ | 22,240 | $ | 10,240 | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized
Cost
|
|
|
Unrealized
Gains
|
|
|
Unrealized
Losses
|
|
|
Fair
Value
|
|
|
Short-term
Investments |
|
|
Investments,
non-current
|
|
||||||
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
||||||
Commercial paper
|
$ | 42,709 | $ | 8 | $ | (16 | ) | $ | 42,701 | $ | 42,701 | $ | — | |||||||||||
Corporate debt securities
|
41,169 | — | (66 | ) | 41,103 | 10,130 | 30,973 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total
|
$ | 83,878 | $ | 8 | $ | (82 | ) | $ | 83,804 | $ | 52,831 | $ | 30,973 | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated
|
|
||
|
|
Amortized
|
|
|
Fair
|
|
||
|
|
Cost
|
|
|
Value
|
|
||
|
|
(in thousands)
|
|
|||||
Due in one year or less
|
$ | 22,258 | $ | 22,240 | ||||
Due after one year through two years
|
10,255 | 10,240 | ||||||
|
|
|
|
|||||
$ | 32,513 | $ | 32,480 | |||||
|
|
|
|
June 30, 2021
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
(in thousands)
|
||||||||||||||||
Assets:
|
||||||||||||||||
Money markets funds (included in cash equivalents)
|
$ | 61,907 | $ | — | $ | — | $ | 61,907 | ||||||||
Commercial paper
|
— | 2,991 | — | 2,991 | ||||||||||||
Corporate debt securities
|
— | 29,489 | — | 29,489 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets
|
$ | 61,907 | $ | 32,480 | $ | — | $ | 94,387 | ||||||||
|
|
|
|
|
|
|
|
|
|
December 31, 2020
|
|
|||||||||||||
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
||||
|
|
(in thousands)
|
|
|||||||||||||
Assets:
|
|
|
|
|
||||||||||||
Money markets funds (included in cash equivalents)
|
$ | 7,839 | $ | — | $ | — | $ | 7,839 | ||||||||
Commercial paper
|
— | 42,701 | — | 42,701 | ||||||||||||
Corporate debt securities
|
— | 41,103 | — | 41,103 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total assets
|
$ | 7,839 | $ | 83,804 | $ | — | $ | 91,643 |
June 30,
|
December 31,
|
|||||||
2021
|
2020
|
|||||||
(in thousands)
|
||||||||
Payroll and employee related expenses
|
$ | 1,677 | $ | 1,555 | ||||
External research and development
|
2,077 | 3,633 | ||||||
Other accrued expenses
|
750 | 390 | ||||||
|
|
|
|
|||||
Total accrued expenses
|
$ | 4,504 | $ | 5,578 | ||||
|
|
|
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
(in thousands)
|
(in thousands)
|
|||||||||||||||
Research and development
|
$ | 608 | $ | 39 | $ | 1,094 | $ | 78 | ||||||||
General and administrative
|
879 | 61 | 1,609 | 123 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total stock-based compensation expense
|
$ | 1,487 | $ | 100 | $ | 2,703 | $ | 201 | ||||||||
|
|
|
|
|
|
|
|
June 30,
|
||||||||
2021
|
2020
|
|||||||
Options to purchase common stock
|
3,284,323 | 1,073,044 | ||||||
Redeemable convertible preferred stock
|
— | 14,948,249 |
Item 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
•
|
|
prepare for, initiate and conduct additional clinical trials and preclinical studies of vidutolimod, including, among others, our current Phase 2 trial in
anti-PD-1
anti-PD-1
anti-PD-1
|
|
•
|
|
conduct the necessary
scale-up
activities to support the potential commercialization of vidutolimod, if approved;
|
|
•
|
|
hire additional clinical and scientific personnel to support our ongoing preclinical activities and clinical trials of vidutolimod and any other product candidates we choose to develop;
|
• |
develop any future product candidates;
|
• |
seek marketing approval for vidutolimod and any other product candidates that successfully complete clinical development;
|
• |
acquire or
in-license
additional product candidates;
|
• |
maintain compliance with applicable regulatory requirements;
|
• |
maintain, expand, protect and enforce our intellectual property portfolio;
|
• |
develop and expand our sales, marketing and distribution capabilities for vidutolimod and any other product candidates for which we obtain marketing approval;
|
• |
take precautionary measures to help minimize the risk of the coronavirus or any other future pandemic to our employees and encounter continued delays or interruptions related to current development activities, our supply chain, or the third-parties on whom we rely due to the
COVID-19
pandemic;
|
• |
expand our infrastructure and facilities to accommodate the planned growth of our employee base; and
|
• |
expand our operational, financial and management systems and increase administrative personnel, including to support our clinical development and commercialization efforts and our operations as a public company.
|
• |
expenses incurred in connection with the preclinical and clinical development of our technology and vidutolimod, including clinical trials under agreements with contract research organizations (“CROs”), clinical investigators and consultants;
|
• |
employee-related expenses, including salaries, benefits and travel and stock-based compensation expense, for employees engaged in research and development functions;
|
• |
the cost of contract manufacturing organizations (“CMOs”), that manufacture drug product for use in our preclinical studies and clinical trials and perform analytical testing,
scale-up
and other services in connection with our development activities;
|
• |
costs related to compliance with regulatory requirements;
|
• |
payments made under third-party licensing agreements, such as the exclusive license agreement we entered into with Cytos Biotechnology LTD (now Kuros Biosciences AG, or “Kuros”) (the “Kuros License Agreement”);
|
• |
facilities and other expenses, which include direct and allocated expenses for facilities, insurance and supplies; and
|
• |
costs related to compliance with regulatory requirements.
|
• |
the scope, progress, outcome and costs of our preclinical studies and clinical trials for vidutolimod or any other product candidates we may acquire or develop;
|
• |
making arrangements with third-party manufacturers for both clinical and commercial supplies of vidutolimod or any other product candidates;
|
• |
successful patient enrollment in, and the initiation and completion of clinical trials;
|
• |
raising additional funds necessary to complete clinical development and the potential commercialization, of vidutolimod or any other product candidates;
|
• |
receipt, timing and related terms of marketing approvals from applicable regulatory authorities;
|
• |
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
|
• |
developing and implementing marketing and reimbursement strategies;
|
• |
establishing sales, marketing and distribution capabilities and launching commercial sales of vidutolimod or any other products, if approved, whether alone or in collaboration with others;
|
• |
acceptance of vidutolimod or any other products, if approved, by patients, the medical community and third-party payors;
|
• |
effectively competing with other therapies and/or changes in standard of care;
|
• |
obtaining and maintaining third-party coverage and adequate reimbursement;
|
• |
obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates;
|
• |
protecting and enforcing our rights in our intellectual property portfolio;
|
• |
significant and changing government regulations; and
|
• |
maintaining an acceptable tolerability profile of the products following approval, if any.
|
Three months ended
|
Six months ended
|
|||||||||||||||||||||||
June 30,
|
Increase
|
June 30,
|
Increase
|
|||||||||||||||||||||
2021
|
2020
|
(Decrease)
|
2021
|
2020
|
(Decrease)
|
|||||||||||||||||||
(unaudited,
in
thousands)
|
||||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||
Research and development
|
$ | 14,865 | $ | 6,476 | $ | 8,389 | $ | 25,243 | $ | 12,789 | $ | 12,454 | ||||||||||||
General and administrative
|
4,090 | 1,795 | 2,295 | 7,893 | 3,305 | 4,588 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total operating expenses
|
18,955 | 8,271 | 10,684 | 33,136 | 16,094 | 17,042 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Loss from operations
|
(18,955 | ) | (8,271 | ) | 10,684 | (33,136 | ) | (16,094 | ) | 17,042 | ||||||||||||||
Total other income (expense), net
|
(15 | ) | (77 | ) | (62 | ) | 38 | (55 | ) | 93 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Net loss
|
$ | (18,970 | ) | $ | (8,348 | ) | $ | 10,622 | $ | (33,098 | ) | $ | (16,149 | ) | $ | 16,949 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended June 30,
|
Increase
|
|||||||||||
2021
|
2020
|
(Decrease)
|
||||||||||
( in thousands)
|
||||||||||||
Net cash used in operating activities
|
$ | (29,696 | ) | $ | (16,042 | ) | $ | 13,654 | ||||
Net cash provided by investing activities
|
49,617 | — | 49,617 | |||||||||
Net cash provided by financing activities
|
134 | 92,146 | (92,012 | ) | ||||||||
|
|
|
|
|
|
|||||||
Net increase in cash, cash equivalents and restricted cash
|
$ | 20,055 | $ | 76,104 | $ | (56,049 | ) | |||||
|
|
|
|
|
|
• |
the initiation, progress, timing, costs and results of current and future preclinical studies and clinical trials for vidutolimod and any other product candidates we may develop or acquire in the future;
|
• |
the cost and timing of the manufacture of additional clinical trial materials and the completion of commercial-scale outsourced manufacturing activities;
|
• |
the costs to seek regulatory approvals for any product candidates that successfully complete clinical trials;
|
• |
the extent to which we experience delays or interruptions to preclinical studies and clinical trials, to our third-party service providers on whom we rely, or to our supply chain due to the
COVID-19
pandemic;
|
• |
the need to hire additional clinical, quality assurance, quality control and other scientific personnel
|
• |
the number and characteristics of product candidates that we develop or may
in-license;
|
• |
the outcome, timing and cost of meeting and maintaining compliance with regulatory requirements established by the U.S. Food and Drug Administration (the “FDA”), the European Medical Agency (the “EMA”) and other comparable foreign regulatory authorities;
|
• |
the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
|
• |
the terms of any collaboration agreements we may choose to enter into;
|
• |
the cost associated with the expansion of our operational, financial and management systems and increased personnel, including personnel to support our operations as a public company; and
|
• |
the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products, if approved, on our own.
|
• |
initiating and completing preclinical and clinical development of vidutolimod and future product candidates, including our current Phase 2 trial for
anti-PD-1
|
• |
obtaining regulatory and marketing approvals for vidutolimod and future product candidates for which we complete clinical trials;
|
• |
achieving and maintaining compliance with all regulatory requirements applicable to vidutolimod or any other product candidates;
|
• |
establishing and maintaining commercially viable supply and manufacturing relationships with third parties for vidutolimod and future product candidates;
|
• |
launching and commercializing vidutolimod, if approved, and future product candidates for which we obtain marketing approvals, either directly or with a collaborator or distributor;
|
• |
obtaining market acceptance of vidutolimod, if approved, and future product candidates as viable treatment options by patients, the medical community and third-party payors;
|
• |
addressing any competing technological and market developments;
|
• |
identifying, assessing, acquiring and developing new product candidates;
|
• |
negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
|
• |
obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and
know-how;
and
|
• |
attracting, hiring, and retaining qualified personnel.
|
• |
the scope, progress, results and costs of researching and developing vidutolimod and our VLP technology and future product candidates, and conducting preclinical studies and clinical trials, including our current Phase 2 trial for
anti-PD-1
COVID-19
(the
“COVID-19
pandemic”), discussed below;
|
• |
the timing of, and the costs involved in, obtaining regulatory and marketing approvals for vidutolimod and future product candidates if clinical trials are successful;
|
• |
the success of existing or any future collaborations;
|
• |
the cost of commercialization activities for any approved product, including marketing, sales and distribution costs;
|
• |
the cost of manufacturing vidutolimod and future product candidates for clinical trials;
|
• |
our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements, including the Kuros License Agreement, the BMS CTCSA and the Regeneron SNLA;
|
• |
the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;
|
• |
the timing, receipt, and amount of sales of, or royalties on, our future products, if any; and
|
• |
the emergence, and regulatory approval, of competing cancer therapies and other adverse market developments.
|
• |
we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials;
|
• |
the FDA, comparable foreign regulators or IRBs may not authorize us or our investigators to commence a clinical trial, to conduct a clinical trial at a prospective trial site or to amend trial protocols, or such regulators or IRBs may require that we modify or amend our clinical trial protocols in ways that make further clinical trials impractical or not financially prudent;
|
• |
we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations (“CROs”);
|
• |
we may be unable to initiate or complete preclinical studies or clinical trials on time or at all due to the evolving impacts of the
COVID-19
pandemic, and the spread of
COVID-19
may affect the operations of research sites, CROs, IRBs, or key governmental agencies, such as the FDA, which may delay the development of vidutolimod or any future product candidates;
|
• |
the supply or quality of raw materials or manufactured product candidates (whether provided by us or third parties) or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or in a timely manner, or we may experience interruptions in supply;
|
• |
the number of patients required for clinical trials of vidutolimod and future product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or be lost to
follow-up
at a higher rate than we anticipate;
|
• |
patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration;
|
• |
clinical trial participants may elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as vidutolimod and future product candidates;
|
• |
our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, and we may be required to engage in additional clinical trial site monitoring to review our contractors’ performance;
|
• |
we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics of the product candidate, or if such undesirable effects are found to be caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;
|
• |
clinical trials of vidutolimod and future product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials, analyses, reports, data, or preclinical trials or abandon product development programs;
|
• |
regulators may revise the requirements for approving our product candidates, or such requirements may not be as we expect or statutes, regulations clinical trial or site policies could be amended or new ones could be adopted;
|
• |
the cost of clinical trials of vidutolimod and future product candidates may be greater than we anticipate or we may have insufficient funds or resources to pursue or complete certain aspects of our clinical trial program or to do so within the timeframes we planned;
|
• |
we may have insufficient funds to pay the substantial user fees required by the FDA upon the submission of a BLA or equivalent authorizations from comparable foreign regulatory authorities;
|
• |
we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;
|
• |
there may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding vidutolimod and future product candidates;
|
• |
the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;
|
• |
the FDA or comparable foreign regulatory authorities may disagree with our proposed indications, fail to approve or subsequently find fault with the manufacturing processes or our manufacturing facilities for clinical and future commercial supplies, and may take longer than we anticipate to review any regulatory submissions we may make for vidutolimod or any future product candidates;
|
• |
the data collected from clinical trials of vidutolimod and future product candidates may not be sufficient for or to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
|
• |
we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development; and
|
• |
regarding trials managed by our existing or any future collaborators, our collaborators may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but potentially suboptimal for us.
|
• |
the design of the clinical trial;
|
• |
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
|
• |
our ability to administer vidutolimod according to the protocol dose, schedule and route of administration;
|
• |
our ability to obtain and maintain patient consents;
|
• |
reporting of the preliminary results of any of our clinical trials;
|
• |
the ability to monitor patients adequately during and after treatment; and
|
• |
the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion.
|
• |
launching commercial sales of vidutolimod and future product candidates, whether alone or in collaboration with others;
|
• |
receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain safety or other limitations that would impede our ability to market vidutolimod or any future product candidates;
|
• |
creating market demand for our product candidates through marketing, sales and promotion activities;
|
• |
hiring, training, and deploying a sales force or contracting with third parties to commercialize vidutolimod or any future product candidates in the United States;
|
• |
manufacturing, either on our own or through third parties, product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;
|
• |
establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;
|
• |
creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets where we receive marketing approval;
|
• |
maintaining patent and trade secret protection and regulatory exclusivity for vidutolimod or any future product candidates;
|
• |
achieving market acceptance of vidutolimod or any future product candidates by patients, the medical community, and third-party payors;
|
• |
achieving appropriate reimbursement for vidutolimod or any future product candidates;
|
• |
effectively competing with other therapies; and
|
• |
maintaining an acceptable tolerability profile of vidutolimod or any future product candidates following launch.
|
• |
the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;
|
• |
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe vidutolimod or any future product candidates;
|
• |
our inability to effectively oversee a geographically dispersed sales and marketing team;
|
• |
the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;
|
• |
an inability to secure adequate coverage and reimbursement by government and private health plans;
|
• |
the clinical indications for which the products are approved and the claims that we may make for the products;
|
• |
limitations or warnings, including distribution or use restrictions, contained in the product’s approved labeling;
|
• |
any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a mandatory REMS or voluntary risk management plan;
|
• |
liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;
|
• |
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
|
• |
unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.
|
• |
the efficacy of our vidutolimod and our VLP modality, and future product candidates alone or in combination with checkpoint inhibitor immunotherapies or other therapies;
|
• |
the commercial success of the checkpoint blockade drugs with which vidutolimod or future products are or may be
co-administered;
|
• |
the prevalence and severity of adverse events associated with vidutolimod and future product candidates or those products with which they are
co-administered;
|
• |
the clinical indications for which the products are approved and the approved claims that we may make for the products;
|
• |
limitations or warnings contained in the product’s
FDA-approved
labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for vidutolimod and future product candidates that may be more restrictive than other competitive products;
|
• |
changes in the standard of care for the targeted indications for vidutolimod and future product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;
|
• |
the relative convenience and ease of administration of vidutolimod and future product candidates and any products with which they are
co-administered;
|
• |
the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;
|
• |
the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;
|
• |
the price concessions required by third-party payors to obtain coverage;
|
• |
the extent and strength of our marketing and distribution of vidutolimod and future product candidates;
|
• |
the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;
|
• |
distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to vidutolimod and future product candidates or to which we agree as part of a REMS or voluntary risk management plan;
|
• |
the timing of market introduction of vidutolimod and future product candidates, as well as competitive products;
|
• |
our ability to offer vidutolimod and future product candidates for sale at competitive prices;
|
• |
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
|
• |
the extent and strength of our third-party manufacturer and supplier support;
|
• |
the actions of companies that market any products with which vidutolimod and future product candidates are
co-administered;
|
• |
the approval of other new products;
|
• |
adverse publicity about vidutolimod and future product candidates or any products with which they are
co-administered,
or favorable publicity about competitive products; and
|
• |
potential product liability claims.
|
• |
decreased demand for any of vidutolimod and future product candidates that we may develop;
|
• |
injury to our reputation and significant negative media attention;
|
• |
regulatory investigations that could require costly recalls or product modifications;
|
• |
withdrawal of clinical trial participants;
|
• |
significant costs to defend the related litigation;
|
• |
substantial monetary awards to trial participants or patients;
|
• |
loss of revenue;
|
• |
the diversion of management’s attention away from managing our business; and
|
• |
the inability to commercialize vidutolimod and future product candidates that we may develop.
|
• |
a covered benefit under its health plan;
|
• |
safe, effective and medically necessary;
|
• |
appropriate for the specific patient;
|
• |
cost-effective; and
|
• |
neither experimental nor investigational.
|
• |
delays or difficulties in enrolling patients in our clinical trials;
|
• |
delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
|
• |
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials or absenteeism due to the
COVID-19
pandemic that reduces site resources;
|
• |
interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;
|
• |
risk that participants enrolled in our clinical trials will contract
COVID-19
or variants thereof while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events or patient withdrawals from our trials;
|
• |
limitations in employee resources that would otherwise be focused on conducting our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
|
• |
delays in receiving authorizations from local regulatory authorities to initiate our planned clinical trials;
|
• |
delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;
|
• |
interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;
|
• |
changes in local regulations as part of a response to the
COVID-19
pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
|
• |
interruptions or delays in preclinical studies due to restricted or limited operations at research and development laboratory facilities;
|
• |
delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and
|
• |
refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.
|
• |
be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other conditions of approval;
|
• |
contain significant safety warnings, including boxed warnings, contraindications, and precautions;
|
• |
not be approved with label statements necessary or desirable for successful commercialization; or
|
• |
contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a REMS to monitor the safety or efficacy of the products.
|
• |
restrictions on manufacturing, distribution, or marketing of such products;
|
• |
restrictions on the labeling, including required additional warnings, such as boxed warnings, contraindications, precautions, and restrictions on the approved indication or use;
|
• |
modifications to promotional pieces;
|
• |
issuance of corrective information;
|
• |
requirements to conduct post-marketing studies or other clinical trials;
|
• |
clinical holds or termination of clinical trials;
|
• |
requirements to establish or modify a REMS or similar strategy;
|
• |
changes to the way the product is administered to patients;
|
• |
liability for harm caused to patients or subjects;
|
• |
reputational harm;
|
• |
the product becoming less competitive;
|
• |
warning or untitled letters;
|
• |
suspension of marketing or withdrawal of the products from the market;
|
• |
regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product;
|
• |
refusal to approve pending applications or supplements to approved applications that we submit;
|
• |
recalls of products;
|
• |
fines, restitution or disgorgement of profits or revenues;
|
• |
suspension or withdrawal of marketing approvals;
|
• |
refusal to permit the import or export of our products;
|
• |
product seizure or detention;
|
• |
FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or
|
• |
injunctions or the imposition of civil or criminal penalties, including imprisonment.
|
• |
the demand for vidutolimod and future product candidates, if we obtain regulatory approval;
|
• |
our ability to set a price that we believe is fair for our products;
|
• |
our ability to obtain coverage and reimbursement approval for a product;
|
• |
our ability to generate revenue and achieve or maintain profitability;
|
• |
the level of taxes that we are required to pay; and
|
• |
the availability of capital.
|
• |
the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
|
• |
the federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;
|
• |
the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
|
• |
the federal physician payment transparency requirements, sometimes referred to as the “Sunshine Act” under the ACA require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report to HHS information related to physician (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) payments and other transfers of value and the ownership and investment interests of such physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain nonphysician providers such as physician assistants and nurse practitioners;
|
• |
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”) and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
|
• |
analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental
third-party payors, including private insurers, and may be broader in scope than their federal equivalents; some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures; and
|
• |
state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts, and analogous foreign laws and regulations.
|
• |
our customers’ ability to obtain reimbursement for vidutolimod and future product candidates in foreign markets;
|
• |
our inability to directly control commercial activities because we are relying on third parties;
|
• |
the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
|
• |
different medical practices and customs in foreign countries affecting acceptance in the marketplace;
|
• |
import or export licensing requirements;
|
• |
longer accounts receivable collection times;
|
• |
longer lead times for shipping;
|
• |
language barriers for technical training;
|
• |
reduced protection of intellectual property rights in some foreign countries;
|
• |
potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
|
• |
the existence of additional potentially relevant third-party intellectual property rights;
|
• |
foreign currency exchange rate fluctuations; and
|
• |
the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.
|
• |
the scope of rights granted under the license agreement and other interpretation-related issues;
|
• |
the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
|
• |
the sublicensing of patent and other rights under our collaborative development relationships;
|
• |
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
|
• |
the inventorship and ownership of inventions and
know-how
resulting from the joint creation or use of intellectual property by our licensors and us and our third-party vendors; and
|
• |
the priority of invention of patented technology.
|
• |
we, or our current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
|
• |
others may independently develop similar or alternative technologies or duplicate our technology without infringing our owned or
in-licensed
intellectual property rights;
|
• |
it is possible that our pending patent applications or those we may own or
in-license
in the future will not lead to issued patents;
|
• |
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
|
• |
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
|
• |
we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;
|
• |
we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;
|
• |
we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
|
• |
we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;
|
• |
we may not develop additional proprietary technologies that are patentable;
|
• |
the patents of others may harm our business; and
|
• |
we may choose not to file a patent in order to maintain certain trade secrets or
know-how,
and a third party may subsequently file a patent covering such intellectual property.
|
• |
failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
|
• |
breach of the manufacturing agreement by the third party;
|
• |
failure to manufacture our product according to our specifications;
|
• |
failure to manufacture our product according to our schedule or at all;
|
• |
production difficulties caused by unforeseen events that may delay the availability of one or more of the necessary raw materials or delay the manufacture of vidutolimod or any future product candidates for use in clinical trials or for commercial supply, including as a result of the
COVID-19
pandemic;
|
• |
misappropriation of our proprietary information, including our trade secrets and
know-how;
and
|
• |
termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
|
• |
collaborators may not perform their obligations as expected;
|
• |
collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
|
• |
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
|
• |
collaborators could fail to make timely regulatory submissions for a product candidate;
|
• |
collaborators may control the public release of information regarding the developments, and we may not be able to make announcements or data presentations on a schedule favorable to us;
|
• |
collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;
|
• |
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
|
• |
product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of vidutolimod and future product candidates;
|
• |
a collaborator with marketing and distribution rights to vidutolimod or any future product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;
|
• |
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates or might result in litigation or arbitration, any of which would be time consuming and expensive;
|
• |
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and
|
• |
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.
|
• |
increased operating expenses and cash requirements;
|
• |
the assumption of additional indebtedness or contingent liabilities;
|
• |
the issuance of our equity securities;
|
• |
assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;
|
• |
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
|
• |
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
|
• |
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and
|
• |
our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.
|
• |
the success of competitive drugs or technologies;
|
• |
results of clinical trials of vidutolimod and future product candidates or those of our competitors, including interim or topline results;
|
• |
regulatory or legal developments in the United States and other countries;
|
• |
the regulatory status of our product candidates;
|
• |
failure of any of our product candidates, if approved, to achieve commercial success;
|
• |
developments or disputes concerning patent applications, issued patents or other proprietary rights;
|
• |
the recruitment or departure of key personnel;
|
• |
the level of expenses related to any of vidutolimod and future product candidates or clinical development programs;
|
• |
the results of our efforts to discover, develop, acquire or
in-license
future product candidates or drugs;
|
• |
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
|
• |
variations in our financial results or those of companies that are perceived to be similar to us;
|
• |
changes in the structure of healthcare payment systems;
|
• |
market conditions in the pharmaceutical and biotechnology sectors;
|
• |
the impact of the ongoing
COVID-19
pandemic on us or on the U.S. and global economies and global equity markets;
|
• |
general economic, industry and market conditions; and
|
• |
the other factors described in this “Risk Factors” section.
|
• |
a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;
|
• |
a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;
|
• |
a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;
|
• |
advance notice requirements for stockholder proposals and nominations for election to our board of directors;
|
• |
a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than
two-thirds
of all outstanding shares of our voting stock then entitled to vote in the election of directors;
|
• |
a requirement of approval of not less than
two-thirds
of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and
|
• |
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.
|
Exhibit
Number
|
Description
|
|
10.1† | Supply and Non-Exclusive License Agreement, effective as of May 6, 2021, by and between Checkmate Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. | |
31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |
31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |
32.1*(1) | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) |
* |
Filed herewith
|
† |
Portions of this exhibit (indicated by asterisk) have been omitted in accordance with Item 601(b)(10) of Regulation
S-K
|
(1) |
The certifications on Exhibit 32 hereto are deemed to be furnished with this Quarterly Report on Form
10-Q
and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
|
CHECKMATE PHARMACEUTICALS, INC. | ||
By: |
/s/ Barry Labinger
|
|
Barry Labinger | ||
President, Chief Executive Officer and Director | ||
(Principal Executive Officer)
|
By: |
/s/ Robert Dolski
|
|
Robert Dolski | ||
Chief Financial Officer | ||
(Principal Financial Officer)
|
Exhibit 10.1
CONFIDENTIAL
SUPPLY AND NON-EXCLUSIVE LICENSE AGREEMENT
This Supply and Non-Exclusive License Agreement (Agreement), made as of this 6th day of May 2021 (the Effective Date), is by and between Regeneron Pharmaceuticals, Inc. (Regeneron), having a place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 and Checkmate Pharmaceuticals. (Sponsor), having a place of business at 245 Main Street, 2nd Floor, Cambridge MA 02142. Regeneron and Sponsor are each referred to herein individually as Party and collectively Parties.
RECITALS
WHEREAS, Sponsor is developing the Sponsor Product;
WHEREAS, Regeneron is developing the Regeneron Product;
WHEREAS, Sponsor desires to sponsor and perform one or more clinical trials for the treatment of patients with various types of cancer, in which the Sponsor Product and the Regeneron Product would be dosed concurrently or in combination, as more particularly described in the Protocol for such clinical trial; and
WHEREAS, Regeneron desires to supply the Regeneron Product for the performance of each such clinical trial.
NOW, THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions, the Parties, intending to be legally bound, mutually agree as follows:
1. |
DEFINITIONS. For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have the meanings herein specified. |
1.1. Affiliate means, with respect to either Party, a firm, corporation or other entity which directly or indirectly owns or controls said Party, or is owned or controlled by said Party, or is under common ownership or control with said Party. The word control means (i) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity, or (ii) possession, directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities, contract rights, voting rights, corporate governance or otherwise.
1.2. Agreement means this agreement, as amended by the Parties from time to time, and as set forth in the preamble, together with all appendices attached or deemed attached hereto.
1.3. Applicable Law means applicable federal, state, local, national and supra-national laws, statutes, rules and regulations of a Governmental Authority, including any rules, regulations, guidelines or other requirements of any Regulatory Authority, that may be in effect from time to time during the Term and applicable to a particular activity hereunder, including: export control and economic sanctions regulations which prohibit the shipment of United States origin products and technology to certain restricted countries, entities and individuals; all applicable data protection requirements such as those specified in the EU Data Protection Directive (if applicable) and the regulations issued under the United States Health Insurance Portability and Accountability Act of 1996 (HIPAA); and laws and regulations governing payments to healthcare providers.
Regeneron - Confidential
1.4. Business Day means any day other than a Saturday, Sunday or any public holiday in the country where the applicable obligations are to be performed.
1.5. cGMP means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Products.
1.6. Clinical Supply Quality Agreement means a clinical quality agreement entered into by the Parties for a particular Study in accordance with Section 9.11.
1.7. CMC means, with respect to a Product, the information contained in (or that would be contained in) the chemistry, manufacturing and controls section of an IND or application for Regulatory Approval for such Product in the United States, or the equivalent section of corresponding regulatory filings made outside the United States. For the avoidance of doubt, the information described in the preceding sentence is CMC information regardless of what document it is contained in or the form in which it is disclosed.
1.8. Combination means the use of the Sponsor Product and the Regeneron Product in concomitant or sequential administration.
1.9. Combination Invention means any Invention, the practice of which necessarily requires both (1) the presence or direct use of the Sponsor Product, or a TLR9 Agonist or the practice of any Sponsor Intellectual Property, on the one hand, and (2) the presence or direct use of the Regeneron Product or a PD-1 Antagonist or practice of any Regeneron Intellectual Property, on the other hand, in each case (1) and (2) when such Invention is Controlled by Sponsor, by Regeneron, or by both Sponsor and Regeneron.
1.10. Combination Patent Applications has the meaning set forth in Section 11.3.
1.11. Combination Patents has the meaning set forth in Section 11.3.
1.12. Confidential Information means any confidential and proprietary information or Know-How furnished or otherwise made available to one Party by the other Party pursuant to this Agreement or generated in the performance of this Agreement, except to the extent that it can be established by the receiving Party that such information or Know-How: (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party as demonstrated by competent business records; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; (d) was disclosed to the receiving Party by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or (e) was independently developed by the receiving Party without use of or access or reference to the disclosing Partys Confidential Information, as demonstrated by competent business records.
2
Regeneron - Confidential
1.13. Control and Controlled by means, with respect to any Patent, Data or other Intellectual Property right, possession by a Party or its Affiliates (whether by ownership, license grant or other means) of the legal right to assign, grant the right to access or use, or to grant a license or a sublicense to, such Patent, data or other Intellectual Property right as provided for herein without violating the terms of any agreement or other arrangement between such Party (or any of its Affiliates) and any Third Party.
1.14. Delivery has the meaning set forth in Section 9.3 with respect to delivery of the Regeneron Product, and Section 9.4 with respect to the Sponsor Product.
1.15. Effective Date has the meaning set forth in the preamble.
1.16. EMA means the European Medicines Agency and any successor agency(ies) or authority having substantially the same function.
1.17. Exclusions List has the meaning set forth in the definition of Violation.
1.18. FDA means the United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same function.
1.19. FFDCA means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).
1.20. Force Majeure has the meaning set forth in Section 14.4.
1.21. Forecast has the meaning set forth in Section 9.2.
1.22. GCP means the Good Clinical Practices officially published by EMA, FDA and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the testing of the Products.
1.23. Government Official means: (a) any officer or employee of a government or any department, agency or instrument of a government; (b) any Person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (c) any officer or employee of a company or business owned in whole or part by a government; (d) any officer or employee of a public international or multilateral organization such as the World Bank, United Nations or the World Health Organization; who, when such Government Official is acting in an official capacity, or in an official decision making role, has responsibility for performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity to make decisions for or on behalf of a government or any department, agency, or instrument of a government with the potential to affect the business of either of the Parties.
3
Regeneron - Confidential
1.24. Governmental Authority means any court, agency, department, authority or other instrumentality of any national, supra-national, state, county, city or other political subdivision.
1.25. HIPAA has the meaning set forth in the definition of Applicable Law.
1.26. Invention means any development, modification, invention, derivative work or improvement, in each case whether or not patentable, including any Know How, and whether or not protectable as Intellectual Property, which is discovered, conceived, reduced to practice or developed or otherwise made by or on behalf of either Party or any of their Representatives in the performance of a Study Plan hereunder or otherwise generated in the performance of this Agreement.
1.27. IND means an application filed with a Regulatory Authority for authorization to commence clinical trials, including (a) an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b) any equivalent of a United States IND in other countries or regulatory jurisdictions, (e.g., clinical trial application (CTA)), and (c) all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing.
1.28. Intellectual Property means any and all of the following rights whether protected, created or arising under Applicable Law in the United States or any other jurisdiction: ideas, inventions, conceptions, Know-How, data, compositions, results, databases, documentation, reports, materials, writings, and other information, including Patents, trade secrets, registered designs, design rights, copyrights (including rights in computer software and database rights), whether registered or not, and all legal means of establishing rights in and to and the aforesaid rights or property similar to any of the foregoing, in any part of the world, together with the rights to apply for the registration of any such right. For the avoidance of doubt, Intellectual Property for purposes of this Agreement expressly excludes all Trademark rights.
1.29. IRB/EC has the meaning set forth in Section 4.1.
1.30. Joint Patent Application has the meaning set forth in Section 11.3.
1.31. Joint Patents has the meaning set forth in Section 11.3.
1.32. Jointly Owned Invention has the meaning set forth in Section 11.3.
1.33. Know-How means any proprietary information, innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, including manufacturing, use, process, structural, operational and other data and information, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable, that is not generally known or otherwise in the public domain.
1.34. Liability has the meaning set forth in Section 14.1.1.
4
Regeneron - Confidential
1.35. Manufacture, Manufactured, or Manufacturing means all stages of the manufacture of a Product, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch and supply, as applicable.
1.36. New Clinical Trial has the meaning set forth in Section 6.1.
1.37. Non-Conformance means, with respect to any Product, such Product deviates from (a) the applicable specifications for such Product (including, in the case of the Regeneron Product, the Specifications) or (b) any Applicable Law, including cGMP or health, safety or environmental protections.
1.38. Party has the meaning set forth in the preamble.
1.39. Patents means patents, patent disclosures and applications (including all patents issuing thereon), statutory invention registrations, division, continuations, continuations-in-part, substitute applications of the foregoing and any extensions, reissues, restorations and reexaminations thereof, and all patent rights provided by international treaties or conventions, whether created or arising under the laws of the United States or any other jurisdiction.
1.40. PD-1 Antagonist means any molecule that selectively binds to and interferes with or otherwise blocks signaling of the programmed cell death 1 receptor (PD-1) pathway, other than the Regeneron Product.
1.41. Person means any individual, sole proprietorship, partnership, corporation, business trust, joint stock company, trust, unincorporated organization, association, limited liability company, institution, public benefit corporation, joint venture, entity or governmental entity.
1.42. Pharmacovigilance Agreement means a pharmacovigilance agreement entered into by the Parties for a particular Study with respect to the exchange of safety information related to the Regeneron Product (alone or in the Combination) as set forth in Section4.5.
1.43. TLR9 Agonist means any molecule that activates Toll Like Receptor 9 pathway, other than the Sponsor Product.
1.44. Product means the Sponsor Product or the Regeneron Product.
1.45. Project Manager has the meaning set forth in Section 2.5.
1.46. Protocol means a written protocol created pursuant to Section 5.1 for a particular Study, that describes such Study and sets forth specific activities to be performed as part of such Study, as such protocol may be amended from time to time by the SCC.
1.47. Protocol Synopsis means a written summary of the procedural method and design of the applicable Study.
5
Regeneron - Confidential
1.48. Regeneron has the meaning set forth in the preamble.
1.49. Regeneron Indemnitees has the meaning set forth in Section 14.1.1.
1.50. Regeneron Invention means any Invention, the practice of which necessarily requires the presence or direct use of the Regeneron Product or a PD-1 Antagonist or which requires the practice of any Regeneron Intellectual Property, and which is not a Combination Invention.
1.51. Regeneron Intellectual Property means Intellectual Property Controlled by Regeneron as of the Effective Date or during the Term pertaining to the Regeneron Product or a PD-1 Antagonist, including all such Intellectual Property of Regeneron that is provided to Sponsor under this Agreement or is reasonably necessary for the conduct of a Study in accordance with this Agreement.
1.52. Regeneron Product means LIBTAYO® (cemiplimab) provided by Regeneron hereunder. [Redacted]
1.53. Regulatory Approvals means, with respect to a Product and a country, any and all permissions (other than the Manufacturing approvals) required to be obtained from Regulatory Authorities and any other competent authority for the development, registration, importation, use (including use in clinical trials), distribution, sale or marketing of such Product in such country, including any pricing or reimbursement approvals.
1.54. Regulatory Authority means any applicable supra-national, federal, national, regional, state, provincial, or local governmental or regulatory authority, agency, department, bureau, commission, council or other entity (e.g., the FDA and EMA) regulating or otherwise exercising authority with respect to activities contemplated in this Agreement, including the development and commercialization of Products in the Territory.
1.55. Representatives means, with respect to a Party, its Affiliates or any employees, directors, contractors, agents or consultants of such Party or its Affiliates.
1.56. Restricted Period means, with respect to a particular Study and Study Field, [Redacted]
1.57. [Redacted]
6
Regeneron - Confidential
1.58. SCC Dispute has the meaning set forth in Section 2.4.
1.59. Sponsor has the meaning set forth in the preamble.
1.60. Sponsor Indemnitees has the meaning set forth in Section 14.1.2.
1.61. Sponsor Intellectual Property means Intellectual Property Controlled by Sponsor as of the Effective Date or during the Term pertaining to Sponsor Product and including all Intellectual Property of Sponsor that is provided to Regeneron under this Agreement or is reasonably necessary for the conduct of a Study in accordance with this Agreement.
1.62. Sponsor Invention means any Invention, the practice of which necessarily requires the presence or direct use of the Sponsor Product or a TLR9 Agonist, or which requires the practice of any Sponsor Intellectual Property, and which is not a Combination Invention
1.63. Sponsor Product means CMP-001. [Redacted]
1.64. Specifications means, with respect to Regeneron Product, the set of specifications for such Product as set forth in the applicable Clinical Supply Quality Agreement.
1.65. Study means each clinical trial to be conducted by Sponsor under this Agreement pursuant to an executed Study Plan involving the concomitant or sequenced administration of the Combination for the treatment of patients in the applicable Study Field, as more particularly described in the applicable Protocol.
1.66. Study Completion has the meaning set forth in Section 3.9.
1.67. Study Coordination Committee or SCC has the meaning set forth in Section 2.1.
1.68. Study Data means, with respect to a particular Study, all data (including raw data) and results (including Study Results) generated in the performance of the Study Plan for such Study and including results obtained from testing or analysis of biological samples as part of a Study pursuant to the Protocol, if applicable, and any relevant monotherapy data generated in the course of the Study pertaining to the Sponsor Product within the Study Field.
1.69. Study Field means, with respect to a particular Study, the specific type(s) of cancer identified in the Study Plan.
7
Regeneron - Confidential
1.70. Study Plan means, with respect to a particular Study for a particular cancer and patient population, the plan, as it may be amended from time to time upon mutual written agreement of the Parties, for the clinical evaluation of the Combination in such Study for which Regeneron Product is used. The initial Study Plan for the first Study is attached hereto, as Appendix B.
1.71. Study Results has the meaning set forth in Section 3.9.
1.72. Term has the meaning set forth in Section 7.1.
1.73. Territory means worldwide.
1.74. Third Party means any Person other than Sponsor, Regeneron or their respective Affiliates.
1.75. Trademark means any trademark, trade name, service mark, service name, brand, trade dress, logo, slogan, tag line or other indicia or origin of ownership, whether registered or unregistered, including the goodwill and activities associated with each of the foregoing.
1.76. Transfer shall mean any sale, license, transfer, other disposal or the granting of any option to do any of the foregoing.
1.77. Violation means that a Party or any of its officers or directors or any other personnel (or other permitted agents of a Party performing activities hereunder) has been: (1) convicted of any of the felonies identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website, including 42 U.S.C. 1320a-7(a) (http://oig.hhs.gov/exclusions/authorities.asp); (2) identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in the System for Award Management (http://www.sam.gov); (3) listed by any US Federal agency as being suspended, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a (http://www.fda.gov/ora/compliance_ref/debar/) (each of (1), (2) and (3) collectively the Exclusions Lists); or (4) otherwise ineligible under Applicable Law (including United States law or any foreign equivalent) or any government programs for the performance of the Study or any other activities under this Agreement.
2. |
STUDY COORDINATION. |
2.1. Formation. As soon as practical after the Effective Date (but in all cases within thirty (30) days thereafter), the Parties shall form a study coordination committee (the Study Coordination Committee or SCC), made up of an equal number of representatives of Regeneron and Sponsor. SCC members will be agreed by both Parties, such agreement not to be unreasonably withheld or delayed.
8
Regeneron - Confidential
2.2. Meetings. The SCC shall meet as soon as practicable after the Effective Date (with respect to the initial Study) or the effective date of each Study Plan (for each other Study) and then once each calendar quarter, or at such other frequency as is mutually determined by the Parties, until the Study Results for the applicable Study have been provided to Regeneron.
2.3. Role. The SCC shall have the responsibility of coordinating and overseeing the conduct of each Study (and other related activities set forth in the applicable Study Plan, including regulatory activities) and shall enable the exchange of information between the Parties. In particular, the SCC is empowered to:
(i) serve as a forum for discussing Study activities;
(ii) review and approve the initial Study Plan for each Study and any amendments to the applicable Study Plan; For Clarity, Regenerons approval shall only be required for decisions relating to the Combination or the Regeneron Product.
(iii) review and approve the applicable Protocol for each Study and any amendments thereto;
(iv) serve as a forum for discussing strategies to obtain Regulatory Approvals necessary to conduct the applicable Study and for coordinating all regulatory activities (including communications with Regulatory Authorities) for the applicable Study;
(v) serve as a forum for discussing strategies for any diagnostic product to be included in the applicable Study (including the selection of any third party to develop or provide any such diagnostic product for the applicable Study);
(vi) serve as a forum for discussing matters relating to supply and Manufacturing, including Forecasts, specifications, Delivery and Non-Conformances;
(vii) establish and oversee joint sub-teams agreed by the Parties to oversee particular projects or activities within the purview of the SCC; and
(viii) perform such other functions as are set forth herein, or as the Parties may mutually agree in writing.
2.4. Decision Making. The SCC will attempt to reach decisions by consensus, with the Sponsor representatives having collectively one vote and the Regeneron representatives having collectively one vote. If consensus is not achieved on any matter within thirty (30) days (SCC Dispute), the matter will be escalated to the Sponsor CEO and the Regeneron Executive Vice President, Global Clinical Development, provided however that (1) in the event that the matter relates solely to the Regeneron Product (including the dose and dosing regimen for the Regeneron Product) or any diagnostic for the Regeneron Product alone, Regeneron shall have final decision making authority and (2) in the event that the matter relates solely to the Sponsor Product (including the dose and dosing regimen for the Sponsor Product) or any diagnostic for the Sponsor Product alone, Sponsor shall have final decision making authority. If such SCC Dispute is not addressed by clause (1) or (2) of the previous sentence, the dispute shall be resolved as provided for in Article 19.
9
Regeneron - Confidential
2.5. Project Manager. Each Party shall designate a project manager (the Project Manager) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to a given Study. The Project Managers shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information and shall serve as the primary point of contact for any issues arising under this Agreement. The Project Managers shall have the right to attend all SCC meetings and may bring to the attention of the SCC any matters or issues either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree in writing. Prior to any meeting of the SCC, the Sponsor Project Manager shall provide an update in writing to the Regeneron Project Manager, which update shall contain information about overall Study progress, recruitment status, interim analysis (if results are available), final analysis and other information relevant to the conduct of the applicable Study and the applicable Study Data.
3. |
CONDUCT OF THE STUDY. |
3.1. General; Study Plans. The Parties shall perform the initial Study in accordance with this Agreement, including the Study Plan for such Study, which is attached hereto. For each other Study that the Parties agree to perform under this Agreement, the Parties are to complete and execute a Study Plan, which, among other items, shall include the Protocol Synopsis or the draft Protocol attached hereto as Appendix A, for such Study and the obligations and activities to be performed by each Party in connection with such Study (including regulatory activities). Each Study Plan, once mutually agreed, shall be signed by an authorized representative of each Party and, once fully executed, shall be deemed incorporated into this Agreement by this reference. Sponsor shall act as the sponsor of each Study and shall hold each IND relating to each Study. Sponsor shall be solely responsible for designing each Study and for the Protocol therefor, provided that the SCC shall review and approve the Protocol pursuant to Section 2.3 and subject to each Partys decision-making rights as set forth in Section 5.2.
3.2. Compliance. Subject to Section 5.2, Sponsor shall be responsible for operational execution and management of, and will use commercially reasonable efforts to conduct, each Study. Sponsor shall ensure that each Study is performed in accordance with this Agreement, the Protocol for such Study, and all Applicable Laws, including GCP, and shall ensure that its Affiliates and subcontractors performing activities under this Agreement do the same.
3.3. No Violation. Neither Party shall knowingly employ or subcontract with any Person that is in Violation. Each Party hereby certifies that it has not employed or otherwise used in any capacity and will not employ or otherwise use in any capacity the services of any Person in Violation in performing any portion of any Study or other activities under this Agreement, and that each Party has, as of the Effective Date, screened itself, and its officers and directors, against the Exclusions Lists and that it has informed the other Party whether it or any of its officers or directors is in Violation. Each Party shall notify the other Party in writing immediately if any such Violation comes to its attention with respect to any Person performing activities under this Agreement, and shall, with respect to any such Person in Violation, promptly remove such Person from performing activities or acting in any function or capacity related to any Study or otherwise related to activities under this Agreement.
10
Regeneron - Confidential
3.4. Records and Reports. Sponsor shall maintain reports and all related documentation in good scientific manner and in compliance with Applicable Law in connection with each Study. Sponsor shall provide to Regeneron all Study information and documentation reasonably requested by Regeneron to enable Regeneron to (i) comply with any of its legal, regulatory and/or contractual obligations, or any request by any Regulatory Authority, related to the Regeneron Product or (ii) determine whether the applicable Study has been performed in accordance with this Agreement.
3.5. Consent. Sponsor shall ensure that all patient authorizations and consents required under HIPAA, the General Data Protection Regulation (Regulation (EU) 2016/679) (if applicable) or any other similar Applicable Law in connection with each Study are obtained, are valid and permit the sharing of Study Data with Regeneron.
3.6. Study Data Ownership and Copies. [Redacted]
3.7. Restrictions on Use. [Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
11
Regeneron - Confidential
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
3.8. Samples. [Redacted]
12
Regeneron - Confidential
[Redacted]
3.9. Report. Within six (6) months following Study Completion of a given Study in the Study Field, Sponsor shall provide Regeneron with a preliminary draft of the final clinical study report and the tables and listings for such Study (Study Results), in electronic form. Sponsor shall consider in good faith any comments made by Regeneron to such report, and shall not include any statements pertaining to the Regeneron Product (or its use in the Combination) that Regeneron objects to in writing within thirty (30) days of receipt of the draft report, Sponsor shall provide Regeneron with the final version of the clinical study report within a reasonable time following Sponsors receipt of Regenerons comments, but in no event later than the date that is three (3) months after such receipt (or, if Regeneron does not provide comments, after the expiration of the thirty (30) day period following Regenerons receipt of the draft clinical study report). Study Completion for each Study shall occur upon final database lock of such Study.
3.10. License Grants.
3.10.1. Subject to the terms of this Agreement, with respect to each Study, Regeneron hereby grants to Sponsor a non-exclusive, worldwide, non-transferable, royalty-free, limited license under Regeneron Intellectual Property for the Term of this Agreement, solely to the extent necessary to discharge Sponsors obligations under this Agreement with respect to the conduct of its activities under the Study Plan for such Study.
3.10.2. Subject to the terms of this Agreement, with respect to each Study, Sponsor hereby grants to Regeneron a non-exclusive, worldwide, non-transferable, royalty-free, limited license under Sponsor Intellectual Property for the Term of this Agreement, solely to the extent necessary to discharge Regenerons obligations under this Agreement with respect to the conduct of its activities under the Study Plan for such Study.
3.11. Subcontractors; Study Sites, Investigators, and Agreement. Each Party may delegate its activities under a given Study Plan to its own Affiliates without the other Partys consent. Each Party shall have the right to subcontract any portion of its obligations hereunder to Third Party subcontractors without the other Partys consent. Each Party shall remain solely and fully liable for the performance of its Affiliates and subcontractors. Subject to the applicable Clinical Supply Quality Agreement, either Party may, without consulting the other Party, subcontract Manufacturing with regards to either the Sponsor Product or the Regeneron Product, as applicable, to be provided for such Study. Each Party shall ensure that each of its Affiliates and subcontractors performs its obligations in a manner no less restrictive than the terms of this Agreement, including the Appendices attached hereto, and to the extent consistent with pre-existing Third Party agreements; the
13
Regeneron - Confidential
Parties agree that Sponsor shall have no obligation to amend any existing Third Party agreements. Each Party shall obtain and maintain copies of documents relating to the obligations performed by such Affiliates and use commercially reasonable efforts to obtain and have maintained documents relating to the obligations performed by such subcontractors and that are required to be provided to the other Party under this Agreement. Sponsor shall ensure that all clinical trial agreements with Study sites do not conflict with the terms of this Agreement.
4. |
REGULATORY AND SAFETY. |
4.1. Approvals. Sponsor shall ensure that all directions from any Regulatory Authority or institutional review board or ethics committee (IRB/EC) with jurisdiction over a Study are followed. Further, Sponsor shall ensure that all IRB/EC approvals, customs clearances, and Regulatory Approvals for each Study from any Regulatory Authority and/or IRB/EC with jurisdiction over such Study are obtained prior to initiating performance of such Study. Sponsor will be responsible for filing the IND for each Study.
4.2. Interactions with Regulatory Authorities. Regeneron shall have the right (but no obligation) to participate in any discussions between Sponsor and any Regulatory Authority regarding matters related specifically to the Regeneron Product in the Study, and, to the extent reasonably practicable, Sponsor shall provide sufficient advance notice (at least five (5) Business Days, unless a shorter response period is required by the applicable Regulatory Authority, in which case such notice shall be provided to Regeneron as soon as reasonably practicable) to Regeneron of any such discussions. If Sponsor receives any correspondence, comments or other inquiries from a Regulatory Authority that pertain to the Combination or the Regeneron Product, Sponsor shall promptly provide such correspondence, comments or inquiries to Regeneron at least five (5) Business Days before any response is due, unless a shorter response period is required by the applicable Regulatory Authority, in which case such correspondence, comments or inquiries shall be provided to Regeneron as soon as reasonably practicable. For all correspondence, comments or inquiries from a Regulatory Authority that pertain to the Combination, but not solely to the Regeneron Product, Regeneron may provide, and Sponsor will consider in good faith, Regenerons reasonable comments provided within such five (5) Business Day (or if applicable, shorter) period. If such correspondence, comments or other inquiries pertain solely to the Regeneron Product, Regeneron will promptly review and respond within five (5) Business Days (or such shorter period as may be required), and Sponsor will forward such response to the Regulatory Authority on Regenerons behalf. With respect to any correspondence, comments or other inquiries from a Regulatory Authority regarding a Study that pertain specifically to the Regeneron Product, Regeneron shall also be permitted to respond directly to such Regulatory Authority if Regenerons response includes proprietary subject matter regarding Regenerons Product that is not to be shared with the Sponsor. Subject to the conditions set forth in the foregoing sentence, if Regeneron elects to respond directly to such Regulatory Authority, Regeneron shall be responsible for providing its response within the deadline prescribed by such Regulatory Authority (if none, Regeneron shall nonetheless provide such response promptly).
14
Regeneron - Confidential
4.3. Right of Reference. [Redacted]
4.4. Physician Payment Reporting. To the extent that Regeneron is required by Applicable Law to report payments made by Sponsor and its subcontractors to physicians or teaching hospitals, Sponsor shall provide on a timely basis, in consultation with Regeneron, all information necessary to comply with Applicable Law.
4.5. Adverse Event Reporting. Sponsor will be solely responsible for compliance with all Applicable Law pertaining to safety reporting for each Study and related activities. As soon as reasonably practical after the Effective Date, but, in any event, prior to the first dosing of the first patient with the Regeneron Product in the first Study, the Parties will agree upon and execute a Pharmacovigilance Agreement. For all other Studies, the Parties will execute a Pharmacovigilance Agreement as soon as reasonably practicable following the execution of the Study Plan for such Study, but, in any event, prior to the first dosing of the first patient with a Product in the applicable Study. Each Pharmacovigilance Agreement will establish appropriate processes and timelines for exchanging relevant safety data to fulfill local and international regulatory reporting obligations and to facilitate appropriate safety monitoring of the Regeneron Product (alone or in the Combination) in the applicable Study, and shall include safety data exchange procedures governing the coordination, collection, reporting, and exchange of information concerning any adverse experiences, pregnancy reports, and any other safety information arising from or related to the use of the Regeneron Product (alone or in the Combination) in the applicable Study. Such procedures shall be in accordance with, and enable the Parties and their Affiliates to fulfill, all local and international regulatory reporting obligations to Regulatory Authorities and the clinical investigators.
5. |
PROTOCOL AND RELATED DOCUMENTS. |
5.1. Protocol. A Protocol Synopsis or agreed draft Protocol for the initial Study has been agreed to by the Parties as of the Effective Date and a draft Protocol is attached hereto as Appendix A. Within sixty (60) days after the Effective Date, but, in any event, no later than sixty (60) days prior to any meeting with FDA to discuss the draft Protocol for the initial Study if not attached to Appendix A, the Parties shall agree upon a Protocol for such Study, with reference to the draft Protocol attached hereto as Appendix A, subject to each Partys decision-making rights as set forth in Section 5.2. For each other Study, the Sponsor shall prepare and provide to Regeneron a Protocol and, if mutually agreed to by the Parties pursuant to Section 2.3, such Protocol shall be included in the applicable Study Plan executed by the Parties. Any changes to the Protocol (whether or not material) shall require mutual written consent subject to each Partys decision-making rights as set forth in Section 5.2.
15
Regeneron - Confidential
5.2 |
Decision Making. Notwithstanding anything to the contrary in this Agreement including the agreed draft Protocol included in Appendix A, each Party, in its sole discretion, will determine the dose and dosing regimen for such Partys Product and its use in the Combination for any new Study Plan or Protocol not attached to the Agreement as of the Effective Date and will have the final decision on all matters relating to such Partys Product and its use in the Combination (including any changes to the Protocol that would require such Party to provide additional Product) and any information regarding such Partys Product included in the Protocol. In addition, each Party will determine matters relating to any diagnostic to be used for its Product. |
5.3 |
Consent Form. Sponsor shall prepare the patient informed consent form for each Study (it being understood that the portion of the informed consent form relating to the Regeneron Product will be provided by Regeneron). Sponsor shall ensure that any such patient informed consent form complies with GCP requirements and Applicable Laws. |
5.4 |
Financial Disclosure Information. Sponsor shall (a) track and collect financial disclosure information from all clinical investigators involved in each Study and (b) prepare and submit the certification and/or disclosure of the same in accordance with all Applicable Law, including, but not limited to, Part 54 of Title 21 of the United States Code of Federal Regulations (Financial Disclosure by Clinical Investigators) and related FDA Guidance Documents. Sponsor shall track and collect from all clinical investigators involved in each Study one (1) combined certification and/or disclosure form for both Regeneron and Sponsor. For purposes of this Section 5.3, the term clinical investigators shall have the meaning set forth in Part 54.2(d) of Title 21 of the United States Code of Federal Regulations. |
6. |
CERTAIN COVENANTS. |
6.1 Clinical Trials. [Redacted]
16
Regeneron - Confidential
[Redacted]
6.2 Notifications of Potential Transfers in the Study Field. [Redacted]
6.3 No further obligations. Nothing in this Agreement obligates either Party to any further agreement or collaboration related to the products or studies in this Agreement.
7. TERM AND TERMINATION.
7.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until completion of all of the obligations of the Parties hereunder for all Studies, or until terminated by either Party pursuant to this Article 7 (the Term). The Parties shall be entitled to enter into Study Plans during the period of time commencing on the Effective Date and expiring on the fifth (5th) anniversary of the Effective Date.
7.2 Unsafe Use of Regeneron Product. In the event that (a) Regeneron in good faith believes that the Regeneron Product is being used in a manner that represents an unjustified risk to the safety of patients in the Study Field, and Sponsor fails to incorporate changes into the Protocol requested in writing by Regeneron to address such issue, or (b) the Regeneron Product is not being used as described in the Protocol, Regeneron has the right to immediately terminate this Agreement (or any Study being performed under this Agreement) and the supply of the Regeneron Product upon written notice to Sponsor.
7.3 Certain Additional Termination Rights. Either Party may terminate a Study Plan in the event that (1) patient screening for the Study does not commence within twelve (12) months after (a) the Effective Date, with respect to the initial Study, or (b) the execution of the applicable Study Plan, with respect to each other Study or (2) initial patient recruitment for Stage 1 (as defined in the Study Plan) of a Study Plan is not completed within 18 months of (a) the first study subject dosed, with respect to each Study under this Agreement. Sponsor may terminate any Study and related Study Plan if the Parties do not agree to any Protocol or amendment related to such Study within 60 Business Days of the Effective Date. If either Party terminates a Study Plan under this Section 7.3, Sponsor shall return to Regeneron any Regeneron Product it received in connection with such Study Plan. If such Product has past its expiration date, Sponsor shall reimburse Regeneron for such unusable Product if the failure to enroll patients is due to Sponsors failure to use commercially reasonable efforts to enroll trial in a timely matter.
17
Regeneron - Confidential
7.4 Termination for Material Breach. Either Party may terminate this Agreement if the other Party commits a material breach of this Agreement, and such material breach remains uncured thirty (30) days after receipt of written notice thereof from the non-breaching Party; provided that if such material breach cannot reasonably be cured within thirty (30) days, the breaching Party shall be given a reasonable period of time to cure such breach not to exceed one-hundred and twenty (120) days; provided further, that if such material breach is incapable of cure, then the notifying Party may terminate this Agreement effective after the expiration of such thirty (30)- day period. Notwithstanding the foregoing, if any such material breach relates solely to a particular Study and does not reasonably relate to or affect the breaching Partys performance of (or ability to perform) any other Study, then the non-breaching Party shall only have the right under this Section 7.4. to terminate such Study to which the breach relates. If Regeneron terminates for material breach by Sponsor, then Sponsor shall reimburse Regeneron for Regeneron Product it received in connection with the terminated Study to which the breach relates.
7.5 Pharmacovigilance Agreement. Either Party may terminate a particular Study under this Agreement immediately upon written notice to the other Party if (a) the Parties do not execute a Pharmacovigilance Agreement for such Study within the timeframe set forth in Section 4.5 or (b) the terminating Party determines in good faith that such Study may unreasonably adversely affect patient safety.
7.6 Mutual Termination for Regulatory Action; Other Reasons. Either Party may terminate a particular Study (in whole or in part on a country-by-country basis) immediately upon written notice to the other Party in the event that any Regulatory Authority takes any action, or raises any objection, that prohibits the terminating Party from supplying its Product for purposes of such Study. Additionally, either Party shall have the right to terminate a particular Study immediately upon written notice to the other Party in the event that it determines, in its sole discretion, to discontinue development and/or commercialization of its Product within the Study Field for such Study, for medical, scientific or legal reasons. Notwithstanding the foregoing, Regeneron shall continue to supply the Regeneron Product for any already activated sites at the time of termination for patients which have already been enrolled in such trial for the duration of such individual treatment.
7.7 Mutual Termination for Corruption. Either Party shall be entitled to terminate this Agreement immediately upon written notice to the other Party, if such other Party fails to perform its obligations in accordance with Section 13.5. The non-terminating Party shall have no claim against the terminating Party for compensation for any loss of whatever nature by virtue of the termination of this Agreement in accordance with this Section 7.7. To the extent (and only to the extent) that the laws of the Territory provide for any such compensation to be paid to the non-terminating Party upon the termination of this Agreement, the non-terminating Party hereby expressly agrees (to the extent possible under the laws of the Territory) to waive or to repay to the Party terminating this Agreement any such compensation.
7.8 Survival. The provisions of Sections 3.4-3.9, 4, 7.3-7.4, this Section 7.8, 7.9 and Articles 1 (to the extent definitions are used in other surviving provisions), 10-23 shall survive the expiration or termination of this Agreement.
7.9 Effects of Termination.
7.9.1 No Prejudice. Termination of this Agreement shall be without prejudice to any claim or right of action of either Party against the other Party for any prior breach of this Agreement.
18
Regeneron - Confidential
7.9.2 Return of Regeneron Product. Except as otherwise set forth in this Section 7, in the event that this Agreement or any Study is terminated, or in the event Sponsor remains in possession (including through any Affiliate or subcontractor) of Regeneron Product at the end of the Term, Sponsor shall, at Regenerons sole discretion, promptly either return or destroy all such unused Regeneron Product pursuant to Regenerons instructions subject to Section 7.9.4 below. If Regeneron requests that Sponsor destroy the unused Regeneron Product, as the case may be, Sponsor shall provide written certification of such destruction. In the event Sponsor terminates this Agreement pursuant to Section 7.4 except as otherwise agreed, all such return of unused Regeneron Product shall be at Regenerons sole cost and expense and in all other instances shall be at Sponsors sole cost and expense.
7.9.3 Confidential Information. Upon termination of this Agreement, each Party and its Affiliates shall promptly return to the other Party or destroy any Confidential Information of the other Party (other than Study Data and Inventions in which such Party has an ownership interest) furnished to the receiving Party by the other Party, except that the receiving Party shall have the right to retain one copy for record keeping purposes and such retained copy shall be maintained in accordance with the non-disclosure and non-use restrictions set forth in Article 10.
7.9.4 Wind-Down. Upon receipt by either Party of a termination notice of this Agreement, subject to the terms of this Article 7, Sponsor shall submit a wind-down plan to Regeneron setting forth the tasks reasonably necessary or required in connection with the orderly termination of the Study and the proper plan for managing the patients enrolled in the Study, including any actions reasonably required to safely close out the Study or required by Applicable Laws. [Redacted]
8. COSTS OF STUDY PLAN. [Redacted]
19
Regeneron - Confidential
9. SUPPLY AND USE OF THE PRODUCTS.
9.1 Supply. Sponsor and Regeneron will each use commercially reasonable efforts to supply, or cause to be supplied, sufficient quantities of Sponsor Product and Regeneron Product, respectively, to satisfy the requirements of the Study Plan for each Study. Each Party shall also provide to the other Party a contact person for coordination of Product supply under this Agreement. Each Party shall supply its Product in accordance with the terms of this Agreement. Each Party shall notify the other Party as promptly as possible in the event of any Manufacturing delay that is likely to adversely affect supply of a Product as contemplated by this Agreement, and Sponsor and Regeneron shall cooperate to seek to promptly resolve such issue. Notwithstanding the foregoing, or anything to the contrary herein, in the event that either Party is not supplying its Product in accordance with the terms of this Agreement, or is not allocating its Product under procedures agreed to under Section 9.9, then the other Party shall have no obligation to supply its Product, or may allocate proportionally. This Agreement does not create any obligation on the part of Regeneron to provide the Regeneron Product for any activities other than as set forth in a Study Plan, nor does it create any obligation on the part of Sponsor to provide the Sponsor Product for any activities other than those set forth in a Study Plan.
9.2 Forecast. For each Study, the Study Plan shall include a forecast of quantities and delivery dates for the requirements of the Regeneron Product to be supplied under this Agreement for such Study (each a Forecast). If there is any change in the quantity of Regeneron Product required for a Study, Sponsor shall promptly notify Regeneron of such change upon becoming aware of the same. Promptly following receipt of any requested change to any Forecast, Regeneron shall notify Sponsor of its ability to supply the requirements of the modified Forecast. The Parties shall discuss the changes to the Forecast and Regenerons ability to meet any such changes. In the event Regeneron notifies Sponsor that it is able to meet such requirements, then such modified Forecast shall be deemed accepted by Regeneron. If Regeneron notifies Sponsor that it is not able to meet such requirements, then Regeneron, at its option, may prepare and provide Sponsor with a time schedule for additional Manufacturing of the Regeneron Product to satisfy such requirements. Otherwise, the previous Forecast shall apply.
9.3 Delivery; Storage. Regeneron will deliver the Regeneron Product DAP (INCOTERMS 2010) to Sponsors, or its designees, location as specified by Sponsor and agreed to by Regeneron (Delivery with respect to such Regeneron Product). Risk of loss for the Regeneron Product shall transfer from Regeneron to Sponsor at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of Regeneron Product, including all importation or customs taxes or duties, shall be borne by Sponsor. Sponsor will: (a) take delivery of the Regeneron Product supplied hereunder; (b) perform the acceptance procedures allocated to it under the Clinical Supply Quality Agreement; (c) subsequently label and pack (in accordance with Section9.6), and promptly ship the Regeneron Product to the Study sites, in compliance with cGMP, GCP and other Applicable Law and the Clinical Supply Quality Agreement; and (d) provide, at the reasonable request of Regeneron, the following information: any applicable chain of custody forms, in transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Regeneron, and usage and inventory reconciliation documentation related to the Regeneron Product.
9.4 Sponsor Product. As between the Parties, Sponsor is solely responsible, at its own cost, for supplying (including all Manufacturing, acceptance and release testing) the Sponsor Product for each Study Plan, and the subsequent handling, storage, transportation, warehousing and distribution of the Sponsor Product supplied hereunder and shall use commercially reasonable efforts to perform such activities. Sponsor shall ensure that all such activities are conducted in
20
Regeneron - Confidential
compliance with cGMP, GCP and other Applicable Law and that the Sponsor Product meets Sponsors specifications. For purposes of this Agreement, the Delivery of a given quantity of the Sponsor Product shall be deemed to occur when such quantity is packaged for shipment to a Study site or other site as set forth herein.
9.5 Representations and Warranties. [Redacted]
9.6 Labeling and Packaging. Regeneron shall provide the Regeneron Product to Sponsor in the form of unlabeled vials, and Sponsor shall be responsible for labeling, packaging and leafleting such Regeneron Product in accordance with the terms and conditions of the applicable Clinical Supply Quality Agreement and otherwise in accordance with all Applicable Law, including applicable cGMP, GCP, and health, safety and environmental protections. Sponsor shall be responsible for labeling, packaging and leafleting of the Sponsor Product in accordance with all Applicable Law, including applicable cGMP, GCP, and health, safety and environmental protections.
9.7 Use, Handling and Storage. Sponsor shall (a) use the Regeneron Product solely for purposes of performing the Study for which such Regeneron Product was provided; (b) not use the Regeneron Product in any manner that is inconsistent with this Agreement or for any commercial purpose; and (c) use, store, transport, handle and dispose of the Regeneron Product in compliance with Applicable Law and the applicable Clinical Supply Quality Agreement, as well as all instructions of Regeneron. Sponsor shall not reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or underlying information, structure or ideas of the Regeneron Product, and in particular shall not analyze the Regeneron Product by physical, chemical or biochemical means except as necessary to perform its obligations under the applicable Clinical Supply Quality Agreement.
21
Regeneron - Confidential
9.8 Release. A certificate of analysis shall accompany each shipment of the Regeneron Product to Sponsor. Sponsor shall be responsible for any failure of the Regeneron Product to meet the Specifications to the extent caused by shipping, storage or handling conditions after Delivery to Sponsor hereunder. Sponsor shall, upon receipt of Regeneron Product and within the time defined in the applicable Clinical Supply Quality Agreement, perform the acceptance (including testing, if any) procedures allocated to it under such Clinical Supply Quality Agreement. Sponsor shall be solely responsible for taking all steps necessary to determine that Regeneron Product or Sponsor Product, as applicable, is suitable for release before making such Regeneron Product or Sponsor Product, as applicable, available for human use, consistent with the Clinical Supply Quality Agreement.
9.9 Shortage; Allocation. In the event of a shortage of a Product such that a Party reasonably believes that it will not be able to fulfill its supply obligations hereunder with respect to its Product, such Party will provide prompt written notice to the other Party thereof (including the quantity of its Product that such Party reasonably determines it will be able to supply) and, upon request, the Parties will promptly discuss such situation (including how the quantities of Product that such Party is able to supply hereunder will be allocated within the applicable Study). In such event, the Party experiencing such shortage shall use its commercially reasonable efforts to remedy the situation giving rise to such shortage as soon as practicable and to take action to minimize the impact of the shortage on the applicable Study.
9.10 Records. Sponsor will keep complete and accurate written records pertaining to its use and disposition of Regeneron Product (including its storage, shipping (cold chain) and chain of custody activities) and, upon the request of Regeneron made with reasonable notice, will make such records open to review by Regeneron for the purpose of conducting investigations for the determination of Regeneron Product safety and/or efficacy and Sponsors compliance with this Agreement with respect to the Regeneron Product. Such requests for review by Regeneron shall not be made more than once per calendar year unless Regeneron has a reasonable basis for seeking more frequent review. Each Party shall maintain complete and accurate records pertaining to its Manufacture of its Product supplied hereunder, and, upon request of the other Party, will make such records open to review by such other Party for the purpose of confirming such Partys compliance with this Agreement with respect to its Manufacturing obligations hereunder. Such requests for review by the other Party shall not be made more than once per calendar year unless such Party has a reasonable basis for seeking more frequent review.
9.11 Quality. The Parties (or their Affiliates) shall enter into a Clinical Supply Quality Agreement for each Study with respect to the quality assurance of the Regeneron Product supplied by Regeneron hereunder for such Study. The Parties will execute the Clinical Supply Quality Agreement for the initial Study as soon as reasonably practicable following the Effective Date, but in any event, prior to the initiation of the shipment of Regeneron Product for a Study. For all other Studies, the Parties will execute the Clinical Supply Quality Agreement as soon as reasonably practicable following the execution of the Study Plan for such Study, but in any event, prior to the initiation of the shipment of Regeneron Product for such Study. Quality matters related to the Manufacture of Regeneron Product for a particular Study shall be governed by the terms of the Clinical Supply Quality Agreement for such Study, in addition to the relevant quality terms of this Agreement, provided that if there is a conflict between the terms of the applicable Clinical Supply Quality Agreement and the terms of this Agreement with respect to a particular Study, the terms of the Clinical Supply Quality Agreement shall govern with respect to any technical or quality matters and otherwise the terms of this Agreement shall govern.
22
Regeneron - Confidential
Each Party shall implement and perform operating procedures and controls for sampling, stability and other testing of its Product, and for validation, documentation and release of its Product and such other quality assurance and quality control procedures as are required by cGMPs and the applicable Clinical Supply Quality Agreement. Audit and inspection rights, recalls, rejection and non-conformances, in each case, with respect to the Regeneron Product and Sponsor Product, are governed by the terms of the applicable Clinical Supply Quality Agreement.
9.12 Placebo. Where applicable, Sponsor shall be responsible for the Manufacture and supply of placebo, comparator products and diagnostic products, in each case, as applicable and to the extent set forth in the applicable Study Plan; provided that, except as otherwise set forth in a Study Plan, Regeneron shall be responsible for the Manufacture and supply of placebo and diagnostic products for the Regeneron Product. The provisions of this Article 9 applicable to the supply of Product shall also apply to any such placebo or comparator product.
9.13 Supporting Documentation. After release of Regeneron Product by Regeneron (as described in the applicable Clinical Supply Quality Agreement) and concurrent with shipment of Regeneron Product to Sponsor, Regeneron shall provide Sponsor with such certificates and documentation as are described in the applicable Clinical Supply Quality Agreement, which documentation will support release of such Regeneron Product for human use.
9.14 Non-Conformance Determination. In the event that Sponsor becomes aware that the Regeneron Product may have a Non-Conformance, Sponsor shall promptly notify Regeneron by [Redacted]. The Parties shall investigate any Non-Conformance and any discrepancy between them shall be escalated to the head of quality of each Party (or such persons designee) for resolution.
9.15 Replacement. In the event that any proposed or actual shipment of the Regeneron Product (or portion thereof) shall be agreed to have a Non-Conformance at the time of Delivery to Sponsor, then unless otherwise agreed to by the Parties, Regeneron shall replace such Regeneron Product as is found to have a Non-Conformance (with respect to the Regeneron Product that has not yet been administered in the course of performing the applicable Study). [Redacted]
9.16 Non-Conformance of Sponsor Product. Sponsor shall be responsible for, and Regeneron shall have no obligations or liability with respect to, any amounts of Sponsors Product supplied hereunder that is found to have a Non-Conformance. Sponsor shall replace, using diligent efforts, any of Sponsors Product as is found to have a Non-Conformance (with respect to Sponsor Product that has not yet been administered in the course of performing the applicable Study). [Redacted]
23
Regeneron - Confidential
[Redacted]
10. CONFIDENTIALITY.
10.1 Confidential Information. Sponsor and Regeneron agree to hold in confidence any Confidential Information provided or made available by the other Party, and neither Party shall use Confidential Information of the other Party except to fulfill such Partys obligations or exercise such Partys rights under this Agreement. Without limiting the foregoing, Regeneron may not use Confidential Information disclosed by or on behalf of Sponsor relating to the Sponsor Product other than for purposes of performance of a Study Plan or in exercising its rights as set forth in this Agreement. Sponsor may not use Confidential Information disclosed by or on behalf of Regeneron relating to the Regeneron Product other than for purposes of the performance of a Study Plan or in exercising its rights as set forth in this Agreement. Neither Party shall, without the prior written permission of the other Party, disclose any Confidential Information of the other Party to any Third Party except to the extent disclosure (a) is required by Applicable Law; (b) is pursuant to the terms of this Agreement; or (c) is necessary for the conduct of a Study Plan, and (d) provided that the disclosing Party shall otherwise provide reasonable advance notice to the other Party before making such disclosure. For the avoidance of doubt, Sponsor may, without Regenerons consent, disclose Confidential Information to clinical trial sites and clinical trial investigators performing a Study, the data safety monitoring and advisory board relating to a Study, and Regulatory Authorities such as the FDA, EMA or other health authorities working with Sponsor on a Study, in each case to the extent necessary for the performance of the applicable Study and provided that such persons (other than governmental entities) are bound by an obligation of confidentiality at least as stringent as the obligations contained herein. Notwithstanding the foregoing, (i) [Redacted] and (ii) Sponsor may share Confidential Information of Regeneron as set forth in Section 3.7.8.
10.2 Ownership of Certain Confidential Information. Study Data regarding the safety or efficacy of the Regeneron Product alone shall be the Confidential Information of Regeneron and Study Data regarding the safety or efficacy of the Sponsor Product alone shall be the Confidential Information of Sponsor. Study Data regarding the Combination (including the safety of the Combination and/or efficacy in any Study Field) shall be the Confidential Information of both Parties; [Redacted]. The terms and conditions hereof are deemed to constitute both Parties Confidential Information provided that each Party may disclose such terms and conditions to actual or potential investors, acquirors, licensees and collaborators on a need-to-know basis under the same confidentiality requirements set forth in this Section 10 that apply to each of the Parties
24
Regeneron - Confidential
under this Agreement. Inventions that constitute Confidential Information and are jointly owned by the Parties, shall constitute the Confidential Information of both Parties and each Party shall have the right to use such Confidential Information consistent with this Article 10 and Articles 11, 12 and 13. Inventions that constitute Confidential Information and are solely owned by one Party shall constitute the Confidential Information of that Party and each Party shall have the right to use such Confidential Information consistent with this Article 10 and Articles 11, 12 and 13.
10.3 Personally Identifiable Data. All Confidential Information containing personal identifiable data shall be handled in accordance with all applicable data protection and privacy laws, rules and regulations applicable to such Party.
11. INTELLECTUAL PROPERTY.
11.1 Sponsor Inventions. As between Regeneron and Sponsor, Sponsor shall own all right, title and interest in and to Sponsor Inventions and all Intellectual Property rights thereto are the exclusive property of Sponsor, [Redacted]
11.2 Regeneron Inventions. As between Regeneron and Sponsor, Regeneron shall own all right, title and interest in and to Regeneron Inventions and all Intellectual Property rights thereto are the exclusive property of Regeneron, [Redacted]s.
11.3 Combination Inventions. All right, title and interest in and to all Combination Inventions shall belong jointly to Sponsor and Regeneron. [Redacted]
25
Regeneron - Confidential
[Redacted]
[Redacted]
[Redacted]
26
Regeneron - Confidential
11.4 Enforcement; Control. Each Party shall promptly provide the other Party with written notice reasonably detailing any known or alleged infringement or misappropriation by a Third Party of Combination Patents or Joint Patents, as well as any declaratory judgment or similar action alleging the invalidity, unenforceability or non-infringement of Combination Patents or Joint Patents. [Redacted]
11.5 Patent Applications. [Redacted]
11.6 REPRINTS; RIGHTS OF CROSS-REFERENCE. Consistent with applicable copyright and other laws, each Party may use, refer to, and disseminate reprints of scientific, medical and other published articles and materials from journals, conferences and/or symposia relating to a Study Plan, which disclose the name of a Party, provided such use does not constitute an endorsement of any commercial product or service by the other Party.
12. PUBLICATIONS.
12.1 Publicity. Unless otherwise required by Applicable Law (including regulations under any stock exchange on which either Party or its Affiliates is listed), other than the agreed press release set forth on Appendix C hereto, neither Party shall make any public announcement concerning this Agreement or any Study that includes Regeneron Product (including the initial posting to www.clinicaltrials.gov.) or otherwise communicate with any news media without the prior written
27
Regeneron - Confidential
consent of the other Party. Without limiting the previous sentence, to the extent a Party desires to make such public announcement beyond that set forth on Appendix C hereto, such Party shall provide the other Party with a draft thereof at least ten (10) Business Days prior to the date on which such Party would like to make the public announcement, unless such ten day prior notice is not possible in order to comply with Applicable Laws (including regulations under any stock exchange on which either Party or its Affiliates is listed); further provided however, that, in such case such Party shall provide the other Party with as much advance notice as reasonably practicable.
12.2 Registration. Sponsor will register each Study with the Clinical Trials Registry located at www.clinicaltrials.gov as required by Applicable Law.
12.3 Publications. Sponsor shall have the first right to publish Study Data and Study Results subject to Section 13.4 and shall use commercially reasonable efforts to publish or present scientific papers regarding the Study Plan and Study Results in accordance with accepted scientific practice. Regeneron agrees not to publish Study Data or Study Results for any Study prior to the timely publication of Study Data and/or Study Results from such Study by Sponsor.
12.4 Review. The Parties agree that prior to submission of any Study Data or Study Results for publication or presentation or any other dissemination of any such results, including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure:
(i) At least thirty (30) days prior to submission for publication of any paper, letter or any other publication, or fifteen (15) U.S business days prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd rom or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional sixty (60) days in order to allow for actions to be taken to preserve rights for patent protection.
(ii) The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) of this Section 12.4 to modify the publication.
(iii) The publishing Party shall remove all Confidential Information of the other Party (but shall not remove jointly owned Study Data) before finalizing the publication.
12.5 Acknowledgement. Each Party agrees to identify the other Party and acknowledge its support in any press release and any other publication or presentation of the Study Data or Study Results of any Study.
13. REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.
13.1 Mutual Representations and Warranties. Each of Sponsor and Regeneron represents and warrants to the other that it has the full right and authority to enter into this Agreement.
28
Regeneron - Confidential
13.2 Representations and Warranties of Sponsor. Sponsor hereby represents and warrants to Regeneron that: (a) Sponsor has the full right, power and authority to grant all of the rights and licenses granted to Regeneron under this Agreement; (b) it will not transfer to any Third Party except to subcontractors acting on behalf of Sponsor pursuant to this Agreement, or sell or make commercially available any Regeneron Product for any use; (c) it will not use Regeneron Product in any manner that is inconsistent with or in conflict with the rights granted herein without the prior written consent of Regeneron in each instance; and (d) that all of its Representatives that may generate Study Results or Inventions, are, or will be prior to generating Study Results or Inventions, contractually obligated to assign Study Results and Inventions to Sponsor, subject to such Study Sites having reserved rights to use such Study Results and Inventions solely for its non-commercial, internal, patient care, educational, and research purposes.
13.3 Representations and Warranties of Regeneron. Regeneron hereby represents and warrants to Sponsor that Regeneron has the full right, power and authority to grant all of the rights and licenses granted to Sponsor under this Agreement and that all of its Representatives are, or will be prior to generating Study Results or Inventions, contractually obligated to assign Inventions to Regeneron.
13.4 No Guarantee of Results. Sponsor does not undertake that any Study shall lead to any particular result, nor is the success of any Study guaranteed. Neither Party accepts any responsibility for any use that the other Party may make of Study Data nor for advice or information given in connection therewith.
13.5 Anti-Corruption.
(i) In performing their respective obligations hereunder, the Parties acknowledge that the corporate policies of Sponsor and Regeneron and their respective Affiliates require that each Partys business be conducted within the letter and spirit of the law. By signing this Agreement, each Party agrees to conduct the business contemplated herein in a manner which is consistent in all material respects with all Applicable Law, including the U.S. Foreign Corrupt Practices Act, good business ethics, and such Partys ethics and other corporate policies.
(ii) Each Party represents and warrants that it and its Representatives have not, and covenants that it and its Representatives will not, in connection with the performance of this Agreement, directly or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the purpose of (a) influencing, inducing or rewarding any act, omission or decision to secure an improper advantage, (b) improperly assisting it in obtaining or retaining business for it or the other Party or (c) public or commercial bribery.
(iii) Neither Party shall contact or otherwise knowingly meet with any Government Official for the purpose of discussing activities arising out of or in connection with this Agreement without the prior written approval of the other Party, except where such meeting is consistent with the purpose and terms of this Agreement and in compliance with Applicable Law.
29
Regeneron - Confidential
Disclaimer. EXCEPT AS EXPRESSLY PROVIDED HEREIN, REGENERON MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE REGENERON PRODUCT, AND SPONSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE SPONSOR PRODUCT.
14. INSURANCE; INDEMNIFICATION; LIMITATION OF LIABILITY.
14.1. Insurance. Each Party warrants that it maintains a policy or program of insurance or self-insurance at levels sufficient to support the indemnification obligations assumed herein. Without limiting the foregoing, Sponsor shall procure insurance for the performance of each Study and shall add Regeneron as an additional insured under each such policy with respect to the applicable Study. Upon request, a Party shall provide evidence of such insurance.
14.1.1 Indemnification. By Sponsor. [Redacted]
14.1.2 By Regeneron. [Redacted]
14.1.3 [Redacted]. [Redacted]
30
Regeneron - Confidential
14.1.4 Notice of Claim. The obligations of Regeneron and Sponsor under this Section 15.2 are conditioned upon the delivery of written notice to Regeneron or Sponsor, as the case might be, of any potential Liability, as the case may be, within a reasonable time after the indemnified Party becomes aware of such potential Liability. The indemnifying Party will have the right to assume the defense of any suit or claim related to the Liability if it has assumed responsibility for the suit or claim in writing. The indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. The indemnifying Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the indemnified Party, which shall not be unreasonably withheld. It shall be reasonable for the indemnifying Party to withhold consent if the settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the indemnified Party from all Liability with respect thereto or if it imposes any Liability or obligation on the indemnified Party without the prior written consent of the indemnified Party.
14.1.5 [Redacted]
14.2 LIMITATION OF LIABILITY. OTHER THAN WITH RESPECT TO THE OBLIGATIONS OF EACH PARTY UNDER SECTION 15.2, IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR SUBCONTRACTORS) BE LIABLE TO THE OTHER PARTY FOR, NOR SHALL ANY PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS OR DAMAGES FOR LOST OPPORTUNITIES), WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (x) THE MANUFACTURE OR USE OF ANY PRODUCT SUPPLIED HEREUNDER OR (y) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT OR ANY REPRESENTATION, WARRANTY OR COVENANT CONTAINED IN OR MADE PURSUANT TO THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER.
14.3 USE OF NAME. Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement.
14.4 FORCE MAJEURE. If in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such Partys reasonable control (e.g., war, riots, fire, strike, governmental laws), such Party shall be excused from performance to the extent that it is necessarily prevented, hindered or delayed (Force Majeure). The non-performing Party will notify the other Party of such Force Majeure within ten (10) days after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party will use commercially reasonable efforts to remedy its inability to perform.
31
Regeneron - Confidential
14.5 ENTIRE AGREEMENT; MODIFICATION. The Parties agree to the full and complete performance of the mutual covenants contained in this Agreement. This Agreement, together with each Clinical Supply Quality Agreement and each Pharmacovigilance Agreement, constitutes the sole, full and complete agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded by this Agreement. No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the Parties hereto.
15. |
ASSIGNMENT AND PERFORMANCE BY AFFILIATES. Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement without the other Partys consent to one or more of its Affiliates or to a Third Party that merges with, consolidates with or acquires all or substantially all of the business or assets or voting control of the assigning Party, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided that such Affiliates agree to be bound by this Agreement and the applicable Party shall remain responsible for and liable for all acts and omissions of such Partys Affiliate. |
16. |
INVALID PROVISION. If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid or unenforceable provision, the Parties shall negotiate in good faith to agree upon a reasonable provision that is legal, valid and enforceable to carry out as nearly as practicable the original intention of the entire Agreement. |
17. |
TIME OF THE ESSENCE. Notwithstanding anything to the contrary in this Agreement, the Parties agree that time is of the essence for initiation of the initial Studies and that Sponsor shall be free to commence each such Study without Regeneron Product and that no approval, or consent, or consultation from or with Regeneron shall be required in any way related to such initial Studies and Regeneron shall have no rights in any Study Data or any Inventions developed in connection with such initial Study if Regeneron does not commence the supply of Regeneron Product within 60 days of the Effective Date. |
18. |
NO ADDITIONAL OBLIGATIONS. Sponsor and Regeneron have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Studies for which the Parties have agreed to a Study Plan and Protocol. Neither Party is under any obligation to enter into another type of agreement at this time or in the future. |
32
Regeneron - Confidential
19. |
DISPUTE RESOLUTION AND JURISDICTION. |
|
The Parties shall attempt in good faith to settle all disputes arising out of or in connection with this Agreement in an amicable manner. Any claim, dispute or controversy arising out of or relating to this Agreement, including the breach, termination or validity hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State of New York without giving effect to its choice of law principles. The Parties irrevocably and unconditionally submit to the exclusive jurisdiction of the United States District Court for the Southern District of New York (or the New York State Supreme Court in New York County if such federal district court lacks subject matter jurisdiction) solely and specifically for the purposes of any action or proceeding arising out of or in connection with this Agreement. |
|
Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed or maintained notwithstanding any ongoing discussions between the Parties. |
20. |
NOTICES. All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier), or sent by internationally-recognized overnight courier addressed as follows: |
If to Sponsor, to:
[Redacted]
If to Regeneron, to:
[Redacted]
21. |
RELATIONSHIP OF THE PARTIES. The relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a partnership, joint venture, agency or fiduciary relationship. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or take any actions, which are binding on the other Party, except with the prior written consent of the other Party to do so. All persons employed by a Party will be the employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. |
33
Regeneron - Confidential
22. |
COUNTERPARTS AND DUE EXECUTION. This Agreement and any amendment may be executed in two (2) or more counterparts (including by way of facsimile or electronic transmission), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or printers. When executed by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or printers. For clarity, facsimile signatures, electronic signatures and signatures transmitted via PDF shall be treated as original signatures. |
23. |
CONSTRUCTION. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the use of any gender will be applicable to all genders, and the word or is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term including as used herein shall be deemed to be followed by the phrase without limitation or like expression. The term will as used herein means shall. References to Article, Section or Appendix are references to the numbered sections of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise. Except where the context otherwise requires, references to this Agreement shall include the appendices attached to this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied against either Party hereto. |
[Signature page follows]
34
Regeneron - Confidential
IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date.
Regeneron Pharmaceuticals, Inc. | Checkmate Pharmaceuticals, Inc. | |||||||
By: |
|
By: |
|
|||||
Name: |
|
Name: |
|
|||||
Title: |
|
Title: |
|
[Signature Page to Supply and Non-Exclusive License Agreement]
Regeneron - Confidential
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
[Redacted]
Protocol CMP-001-009 | Checkmate Pharmaceuticals, Inc. |
APPENDIX C
DRAFT PRESS RELEASE
Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to
Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)
CAMBRIDGE, Mass., May XX, 2021 Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (Regeneron). Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi.
Checkmate and Regeneron will collaborate on a multi-indication, Phase 2, proof-of-concept clinical trial of vidutolimod in combination with cemiplimab in the following patient cohorts: (a) PD-1 treatment-naïve subjects with cutaneous squamous cell carcinoma (CSCC), (b) subjects with cutaneous squamous cell carcinoma (CSCC) that is refractory to PD-1 blockade, and (c) subjects with Merkel cell carcinoma (MCC) that is refractory to PD-1 blockade. Checkmate will be the sponsor of the clinical trial, and Regeneron will supply cemiplimab.
Were pleased to collaborate with Regeneron as we expand evaluation of vidutolimod as a potent stimulator of innate immune activity to patients with life-threatening non-melanoma skin cancers such as CSCC and MCC, said Barry Labinger, President and Chief Executive Officer of Checkmate. We look forward to advancing vidutolimod in combination with Libtayo to further unlock the capabilities and impact of immuno-oncology therapeutics.
About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the bodys innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.
Regeneron - Confidential |
Protocol CMP-001-009 | Checkmate Pharmaceuticals, Inc. |
Availability of Other Information About Checkmate Pharmaceuticals
Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Forward Looking Statements
Various statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, anticipate, believe, can, could, expect, estimate, design, goal, intend, may, might, objective, plan, predict, project, target, likely, should, will, and would, or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for vidutolimod (CMP-001), and the benefits and related implications of current and future partnerships and/or collaborations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission pursuant to Rule
Regeneron - Confidential |
Protocol CMP-001-009 | Checkmate Pharmaceuticals, Inc. |
424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commissions website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in Checkmates subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.
Investor Contact
Rob Dolski
Chief Financial Officer
rdolski@checkmatepharma.com
Media Contact
Karen Sharma
MacDougall
781-235-3060
ksharma@macbiocom.com
Regeneron - Confidential |
Exhibit 31.1
Certification of Periodic Report under Section 302 of the Sarbanes-Oxley Act of 2002
I, Barry Labinger, certify that:
1. |
I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2021 of Checkmate Pharmaceuticals, Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. |
The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. |
(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313); |
c. |
Evaluated the effectiveness of the registrants disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. |
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. |
The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: August 12, 2021
/s/ Barry Labinger |
Barry Labinger |
President and Chief Executive Officer |
(Principal Executive Officer) |
Exhibit 31.2
Certification of Periodic Report under Section 302 of the Sarbanes-Oxley Act of 2002
I, Robert Dolski, certify that:
1. |
I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2021 of Checkmate Pharmaceuticals, Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. |
The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. |
(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313); |
c. |
Evaluated the effectiveness of the registrants disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. |
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. |
The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: August 12, 2021
/s/ Robert Dolski |
Robert Dolski |
Chief Financial Officer |
(Principal Financial Officer) |
Exhibit 32.1
Certification Of
Principal Executive Officer
Pursuant To 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act Of 2002
In connection with the Quarterly Report on Form 10-Q of Checkmate Pharmaceuticals, Inc. (the Company) for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2) |
The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report. |
Date: August 12, 2021 |
/s/ Barry Labinger |
|||||
Barry Labinger President and Chief Executive Officer (Principal Executive Officer) |
||||||
/s/ Robert Dolski |
||||||
Robert Dolski Chief Financial Officer (Principal Financial Officer) |